Interleukin-1 Beta-A Friend or Foe in Malignancies?

1. Introduction

Many aspects of the multi-facetted biological roles of Interleukin-1 alpha (IL-1α), and its functional homolog, but structurally different relative IL-1β were elucidated by the Dinarello lab [ 1 ]. IL-1α and IL-1β constitute the founding members of the IL-1 family which by now comprises eleven members [ 2 ]. Of note, all IL-1 family members are expressed as zymogens and most require proteasomal cleavage to yield biologically active mature forms. Of these, pro-IL-1β and pro-IL-18 are unique as they are cleaved by activated inflammasomes [ 3 ]. These multi-protein complexes are assembled in response to exogenous and endogenous danger signals and induce activation of caspases that generate bioactive IL-1β and IL-18. IL-1β is generated and released by numerous distinct immune and non-immune cell types rapidly in response to inflammatory signals [ 1 ]. In contrast, IL-1α is rather constitutively expressed in many non-immune cell types, but mainly remains in the cytosol or bound to the cell surface released in case of cell necrosis [ 4 ].

IL-1β acts as an amplifier of immune reactions [ 1 ]. In agreement, IL-1 exerts potent pyrogenic activity. For quite a long time, IL-1 has been widely acknowledged as required for efficient initiation of innate and shaping of adaptive immune responses to resolve acute inflammations [ 2 ]. However, the view of IL-1β as a beneficial immune regulator has been challenged by the finding that gain-of-function mutations in components of inflammasomes result in excessive IL-1β production that contribute to autoimmune [ 5 ] and cause autoinflammatory [ 1 ] diseases. In addition, in the case of chronic inflammation, sustained IL-1β may promote both tumor induction and later on also tumor propagation by different mechanisms [ 2 ]. Interestingly, we and others have shown that a number of anti-tumor therapeutics induces IL-1β production [ 6 ].

This review article aims to summarize our current knowledge on the different layers of regulation of IL-1β expression, and the multi-facetted biological roles of this important cytokine under pathophysiological conditions with a focus on tumor development.

2. Production of IL-1β Requires Two Distinct Signals

The different signaling pathways and transcription factors which elevate IL-1β gene expression in response to proinflammatory mediators, including IL-1β itself, have been thoroughly assessed. Besides transcriptional regulation, the half-life of generated IL-1β mRNA is regulated on posttranscriptional level by RNA-binding proteins. Derived pro-IL-1β protein requires proteolytic cleavage to acquire functional activity. This step is mainly facilitated by active caspase-1 as the effector component of stimulation-induced multi-protein inflammasomes. Altogether, these different layers of regulation allow to fine tune IL-1β production under different pathophysiological conditions as early recognized in human monocytic cells [ 7 , 8 ].

2.1. Gene Expression

The gene structure, expressional regulation, and function of IL-1β are evolutionarily well conserved [ 9 ]. In most studies the characteristics of regulatory elements of the human IL-1β gene promoter have been studied in human monocytic cells.

2.1.1. Transcriptional Gene Regulation

The TATA box containing the core promoter region of the IL-1β gene [ 10 ] harbors two bindings sites each for the myeloid-specific Ets-domain containing transcription factor (TF) PU.1 [ 11 ] and the leucine zipper containing TF CCAAT/enhancer binding protein (C/EBP-)β [ 12 ] ( Figure 1 ). For keratinocytes, a specificity protein-1 (SP-1) binding site within the core promoter was identified as essential for steady state IL-1β mRNA expression [ 13 ]. Inflammatory stimuli such as toll-like receptor (TLR) ligands, tumor necrosis factor-α (TNF-α) or IL-1β itself [ 14 ] converge on activation of the signaling adaptor myeloid differentiation primary response 88 (MyD88) [ 15 ] which, besides other signaling pathways, is known to stimulate C/EBP [ 16 ]. In agreement, C/EBP-β was found to confer upregulation of IL-1β gene expression in response to the TLR4 ligand lipopolysaccharide (LPS) derived from gram-negative bacteria [ 17 , 18 ]. Of note, synergistic interaction of C/EBP-β with PU.1 did not require DNA binding of the former, but resulted from protein-tethered transactivation [ 12 ]. Furthermore, the endogenous danger molecule high mobility group box 1 protein (HMGB1) which is released by necrotic cells [ 19 ] was reported to enhance IL-1β gene expression via interaction with PU.1 as well [ 20 ]. Immediately upstream of the transcription start site, the IL-1β core promoter region also contains a functional binding site for the zinc finger-containing transcriptional repressor KLF4, which is induced by proinflammatory stimuli as well, and thereby limits IL-1β gene expression [ 21 ].

Upstream of the core promoter, a functional nuclear factor kappa-light-chain-enhancer of activated B-cells (NF-κB) binding site was reported to contribute to elevated IL-1β gene expression after stimulation [ 22 ]. MyD88 activation resulted in both direct MyD88/IκB kinase (IKK)-dependent degradation of IκB as a prerequisite for the release of NF-κB dimers and stimulation of mitogen activated protein kinase kinase (MKK) activity [ 23 ]. MyD88 activation was reported to stimulate cold-inducible RNA binding protein (CIRBP) which in turn down-regulated IκB expression and hence promoted IL-1β expression [ 24 ]. Lebedeva and Singh [ 25 ] identified a palindromic AT-rich sequence stretch located closely downstream of the NF-κB site to constitutively inhibit IL-1β promoter activity, but could not identify the transcriptional repressor involved. An inducible glucocorticoid response element (GRE) located upstream of the NF-κB site inhibited IL-1β gene expression in response to dexamethasone which activates the TF glucocorticoid repressor (GR) [ 26 ]. As another layer of negative IL-1β gene regulation, the activated GR was reported to directly inhibit LPS-induced NF-κB and activator protein-1 (AP-1) on protein level [ 27 ]. In addition, GR-induced MKP-1 was shown to repress LPS-induced IL-1β induction via MKK repression by direct protein-protein interaction [ 28 ].

Three closely spaced putative hypoxia-induced factor 1 (HIF1) binding sites were demonstrated to confer hypoxia-induced IL-1β upregulation [ 29 ]. Of note, HIF1 is also induced under stimulatory conditions in antigen presenting cells (APC) [ 30 ]. In line, the aforementioned HIF1 sites also contributed to IL-1β upregulation under according circumstances [ 29 ]. Furthermore, stimulation of myeloid cells with LPS-induced interferon response factors (IRF-)4 and IRF-8, and resulted in activation of PU.1 via protein kinase CK2 mediated phosphorylation [ 31 ]. IRF4/8 and PU.1 engaged a composite binding site and synergized to mediate IL-1β gene transcription [ 32 ]. Gray and coworkers [ 33 ] identified a cAMP-responsive element (CRE) adjacent to the composite PU.1/IRF binding site. This CRE site conferred stimulation of IL-1β gene expression in response to cAMP-elevating agents such as prostaglandin E2 in monocytes. In contrast, cAMP induction prevented LPS-mediated upregulation of IL-1β mRNA in astrocytes [ 34 ].

Different components of the extracellular matrix such as fibronectin, type I collagen, and laminin engage integrin receptors known to result in activation of protein kinase C (PKC) [ 35 ]. Activated PKC in turn stimulated AP-1 and thereby IL-1β gene expression [ 36 ]. In addition, PKC is associated with the MyD88 signaling cascade [ 37 ]. Thus far, no specific AP-1 binding site has been identified within the IL-1β gene promoter. Therefore, it remains possible that the CRE site identified by Gray and coworkers [ 33 ] may be engaged by TF of the AP-1 family as well. GATA-2 as a member of the “GATA” sequence binding TF family has also been implicated in MyD88/MKK transmitted upregulation of IL-1β mRNA expression [ 38 ]. However, none of the several potential GATA binding sites have been delineated as functionally active.

The overall accessibility of IL-1β gene promoter was found to be inhibited by DNA methylation in promyeloid cells while differentiated monocytes were devoid of methylated CpG motifs [ 39 ]. In models of LPS tolerance, phosphorylation of histone H3 serine around the IL-1β gene promoter was reduced and binding of the heterochromatin protein-1 (HP-1) was elevated, which correlated with repressed IL-1β gene expression [ 40 ].

In a systemic sequencing approach, Chen and coworkers [ 41 ] identified a number of single nucleotide polymorphisms (SNP) within the IL-1β gene locus, and performed functional assays identifying four SNP to affect overall promoter activity of stimulated monocytic cells. A mutation within the TATA box (SNP B15 [-31]: T ≥ C) diminished stimulation-induced promoter activity. At the same time, this mutation created a functionally active binding site for the TF Yin Yang 1 (YY1) [ 42 ], known to stimulate or silence gene expression [ 43 ]. SNP B14 (−511: C ≥ T) exerted a pronounced stimulatory effect on transcriptional activity of stimulated monocytic cells, whereas SNP B10 (−1464) and SNP B4 (−3737) moderately decreased overall promoter activity [ 41 ].

In a growing number of studies, the prevalence of those alleles within the IL-1β core (SNP B15 TT>CC) and proximal (SNP B14 TT>CC) promoter that conferred higher IL-1β gene expression was found to be associated with an enhanced susceptibility or aggravated course of disease. This included infectious diseases such as tuberculosis [ 44 ], neurodegenerative diseases such as Alzheimer’s disease [ 45 ], autoimmune and autoinflammatory diseases such as psoriasis [ 46 ] and diabetes type 2 [ 47 ], and the occurrence of tumors such as prostate cancer [ 48 ].

2.1.2. Posttranscriptional Gene Regulation

Expression of human IL-1β has been demonstrated to be regulated not only on transcriptional level, but also by modulation of the IL-1β mRNA half-life. In this regard, Marucha and coworkers [ 49 ] demonstrated that treatment of human neutrophils with proinflammatory cytokines (IL-1β, TNF-α) transiently elevated both de novo IL-1β gene transcription as well as the half-life of IL-1β mRNA. On the contrary, IL-4 was identified as a negative regulator of IL-1β mRNA stability in LPS-stimulated monocytes [ 50 ]. In subsequent studies, the 3’-untranslated region of IL-1β mRNA was demonstrated to contain several functional AU-rich elements (ARE) which are engaged by a class of RNA-binding proteins [ 51 ]. Sirenko and coworkers [ 52 ] detected p38 mitogen-activated protein kinase (MAPK)-dependently activated ARE RNA-binding protein 1 (AUF1) to bind two of these ARE upon surface detachment of monocytes. AUF1 binding attenuated IL-1β mRNA stability. Similarly, we demonstrated that dendritic cells (DC) derived from mice deficient for the ARE-binding factor tristetraprolin were characterized by stronger upregulation of IL-1β mRNA in response to LPS treatment as compared with wild type DC due to a prolonged mRNA half-life [ 53 ].

2.2. Processing of Pro-IL-1β

The biogenesis of most IL-1 family members differs from other cytokines insofar as most IL-1 interleukins are generated as biologically inactive zymogen forms which are proteolytically cleaved [ 54 ]. In the case of IL-1β (and IL-18), N-terminal processing is facilitated in myeloid cell types by caspases which often serve as the effector component of inflammasomes. However, (partial) activation is also conferred by other proteases released by activated neutrophils and mast cells [ 55 ].

2.2.1. Caspases

Cytoplasmic danger receptors that belong to the NLR protein family such as nucleotide-binding oligomerization domain-like receptor family leucine-rich repeat protein (NLRP) 1, NLRP3, and NLR family caspase recruitment domain containing 4 (NLRC4), or other types of danger receptors such as AIM2 (absent In melanoma 2), IFI-16 (interferon gamma inducible protein 16), RIG-1 (retinoic acid inducible gene-1), and MEFV (mediterranean fever) induce the formation of multi-protein inflammasomes in response to engagement by according ligands [ 3 ]. For this, binding of receptor-specific danger signals such as LPS, which specifically activates NLRP3, or flagellin, which is recognized by NLRC4, initiates inflammasome formation via inclusion of the adaptor protein ASC (activating signal cointegrator). These canonical inflammsomes recruit caspase-1 which in a proximity-dependent manner becomes autoproteolytically self-activated [ 56 ]. Dimeric active caspase-1 then mediates cleavage of pro-IL-1β and pro-IL-18.

By now, most studies have assessed the properties of NLRP3-based inflammasomes. In response to inflammation-induced MyD88 signaling, NLRP3 expression is upregulated as a prerequisite for formation of NLRP3 inflammasomes [ 57 ]. Of note, NLRP3 expression is negatively regulated on posttranscriptional level by the myeloid-specific micro-RNA (miR-)223 [ 58 ]. miR-223 has been attributed potent anti-inflammatory function in macrophages [ 59 ] as a consequence of inhibition of TF belonging to the NF-κB, C/EBP and STAT (signal transducer and activator of transcription) families [ 60 ].

On protein level, NLRP3 activity is mediated by deubiquitination as induced by TLR ligands [ 61 ]. NLRP3 oligomerization and activation requires interaction with NEK (NIMA-related kinase) after NLRP3-stimulation associated potassium efflux [ 62 ]. In a positive feedback loop, NLRP3 contributes to activation of NF-κB after microbial infection and application of particulate adjuvants [ 63 ]. However, sustained NLRP3 inflammasome activity is inhibited both by long-term LPS priming as well as inflammation-induced type I interferon (IFN) [ 64 ]. In both cases, nitric oxide synthase type 2 is induced which generates nitric oxide resulting in nitrosylation of NLRP3. Moreover, A20, which confers both ubiquitin ligase and deubiquitinase activities, was identified as a NLRP3-specific inhibitor [ 65 ]. Prostaglandin-induced cAMP serves as an endogenous modifier of NLRP3 inflammasome activation as well. Prostaglandin E receptor 4 (EP4) signaling inhibited inflammasome activity in a protein kinase A (PKA) and exchange protein directly activated by cAMP (EPAC) independent manner [ 66 ]. On the contrary, signaling via EP3 elevated LPS-induced inflammasome activity [ 67 ].

Non-canonical inflammasomes lack a specific endogenous danger receptor, and are comprised of caspase-4 and -5 in human [ 68 ] or caspase-11 in mouse [ 69 ]. These inflammasomes are directly activated by intracellular LPS to confer pro-IL-1β and-IL-18 processing. In both cases, inflammasome activation may also result in lytic cell death, termed pyroptosis, due to cleavage-dependent activation of the pore forming protein gasdermin D [ 70 ]. More recently, an alternative NLRP3-associated inflammasome pathway has been described in human monocytes which is also induced by LPS or the endogenous TLR4 ligand oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine (OxPAPC) [ 71 ]. In contrast to canonical inflammasomes, this pathway does not result in pyroptosis.

Caspase-8 is activated by CD95 and TNF receptor 1 signaling, and mediates cell apoptosis [ 72 ]. However, in a number of studies, caspase-8 was shown to replace caspase-1 as the effector molecule of NLR (NLRP3, NLRC4) and non-NLR (AIM2) inflammasomes [ 73 , 74 ]. In addition, CD95 engagement [ 75 ] and LPS-induced formation of Fas-associated via death domain (FADD)/caspase-8 containing ripoptosomes [ 76 ] resulted in processing of pro-IL-1β in an inflammasome-independent manner.

In a growing number of studies, gain-of-function mutations of inflammasome initiating cytoplasmic danger receptor proteins were demonstrated to mediate an increase in overall IL-1β levels [ 5 ]. Gain-of-function mutations of NLRP3 [ 77 ] and NLRC4 [ 78 ] have been associated with autoimmune diseases which overlap in their symptoms, termed cryopyrin-associated periodic syndromes (CAPS). Interestingly, in CAPS patients with mutated NLRP3, catalytically active extracellular NLRP3 inflammasomes were detected [ 79 ]. These extracellular complexes were also internalized by other macrophages, spreading excessive IL-1β maturation.

Besides gain-of-function mutations of inflammsome proteins, a functional NLRP1 promoter polymorphism resulting in elevated gene expression was associated with increased susceptibility towards rheumatoid arthritis [ 80 ] and generalized vitiligo [ 81 ].

2.2.2. Other Proteases

Neutrophils [ 82 ] and mast cells [ 83 ] store many different proteases in their granules that, upon release, exert divergent anti-pathogenic effects. Of these, elastase and closely related cathepsin G as well as chymase were shown to cleave pro-IL-1β at the same site, some residues upstream of the caspase cleavage site [ 55 ]. Extracellular maturation of IL-1β may be important in case of myeloid cells that shed pro-IL-1β containing membrane microvesicles [ 84 ] that are lysed by ATP [ 85 ]. In addition, the membrane integrity of pro-IL-1β producing leukocytes is disturbed by prolonged exposure to antimicrobial peptides [ 86 ] and as a consequence of inflammasome activation itself (pyroptosis) resulting in release of pro-IL-1β. Besides extracellular cleavage of pro-IL-1β, it remains possible that cathepsin G endogenously generated by leukocytes [ 87 , 88 ] may promotes cleavage of pro-IL-1β too.

3. IL-1β Signaling

3.1. The IL-1 Receptor

The Interleukin-1 receptor (IL-1R) family comprises 10 members which share a highly similar structure. They consist of extracellular immunoglobulin domains as well as a cytoplasmic Toll/IL-1 receptor (TIR) domain, except for IL-1R2 [ 89 ]. Of these receptors, only IL-1R1 and IL-1R2 are able to bind IL-1α and IL-1β as well as the receptor antagonist IL-1Ra [ 90 ]. Since IL-1R2 lacks the TIR domain, it cannot induce signaling upon substrate binding [ 91 , 92 ]. IL-1R2 constitutes a “decoy receptor” due to its capability to bind IL-1 without initiating IL-1 signaling [ 93 ]. IL-1R1 and IL-1R2 are expressed by a plethora of cells including immune cells and others [ 90 ]. Especially T cells, polymorphonuclear leukocytes, DC, monocytes, macrophages, and B cells express IL-1R1 and IL-1R2 [ 90 ]. Furthermore, IL-1R1 is expressed by most epithelial cells [ 90 ]. In mice, IL-1R2 is mainly apparent in neutrophils [ 94 , 95 ]. IL-1R3, the accessory chain of the IL-1R members, is expressed by all IL-1 responsive cell types [ 90 ].

3.2. IL-1β Signaling Cascade

Binding of the agonists IL-1α or IL-1β to IL-1R1 results in conformational changes of the receptor and in the formation of IL-1R1/IL-1R3 complexes ( Figure 2 ) [ 96 , 97 , 98 ]. These conformational changes cause the TIR domain of IL-1R3 to get to close proximity to the TIR domain of IL-1R1 which induces IL-1 signaling [ 99 ]. Alternatively, IL-1 may engage IL-1R, and this complex subsequently engages IL-1R3, without inducing IL-1 signaling [ 90 , 100 ]. In addition, the receptor antagonist IL-1Ra can bind to IL-1R1, and thereby prevents the formation of the IL-1R complex [ 101 ].

Upon formation of the IL-1R complex, the two intracellular TIR domains of IL-1R1 and IL-1R3 recruit the TIR domain-containing adaptor protein MyD88 [ 102 , 103 , 104 , 105 ]. The attracted MyD88 proteins constitue oligomers which form a death domain (DD) important for subsequent signaling [ 106 ]. The DD of MyD88 recruits proteins of the IL-1R-associated kinase (IRAK) family. First, IRAK-4 binds to MyD88 followed by IRAK-1 and-2 [ 107 , 108 ], Toll-interacting protein (Tollip) [ 109 ] as well as Pellino-1 (PELI-1) and-2. PELI-1 and-2 are E3-ubiquitin ligases [ 110 ]. Non-phosphorylated IRAK-1 bound to Tollip is inactive [ 111 ]. When IRAK-1 binds to the IL-1R complex, it is phosphorylated and thereby activated through IRAK-4 activity and dissociates from Tollip and from the IL-1R complex [ 109 , 112 ]. IRAK-1 becomes hyper-autophosphorylated due to its activation by IRAK-4. Then, TRAF6 (TNF receptor-associated factor 6) is recruited to hyperphosphorylated IRAK-1 followed by the activation of its E3 ubiquitin ligase activity [ 113 ]. At the same time, IRAK-4 phosphorylates and activates PELI-1 and-2 [ 114 , 115 ]. TAK1 binding protein (TAB)2 and TAB3 are ubiquitinated by activated PELI or TRAF6 and recruit the TGFβ1-activated kinase (TAK)1/TAB1 complex [ 116 ]. This event results in a conformational change of the complex that leads to autophosphorylation and activation of TAK1 [ 117 , 118 ]. TAK1 phosphorylates and activates downstream kinases such as the MKK or IKK complex which regulate target gene expression [ 119 ]. IRAK-2 can replace IRAK-1, but it lacks the autophosphorylation activity of IRAK-1, and is therefore not targeted for fast degradation [ 120 ]. Thereby, IRAK-1 is a more stable signaling component of the IL-1 pathway [ 90 ].

3.3. IL-1Ra and IL-1R2

IL-1Ra is structurally similar to IL-1α and IL-1β. Therefore, it is a competitor for binding to IL-1R1 [ 121 ]. In contrast to IL-1α and IL-1β, IL-1Ra blocks the downstream IL-1 signaling pathway by preventing the binding of IL-1R3 to IL-1 binding IL-1R1 [ 98 ]. Interestingly, IL-1Ra does not bind to IL-1R2 [ 122 ]. Four isoforms of IL-1Ra are known, one secreted isoform and three intracellular isoforms [ 121 ]. Only the secreted isoform has been characterized yet [ 122 ]. Bellehumeur and coworkers showed that human endometrial cells respond to IL-1β by increasing the levels of IL-1R1 and IL-1Ra by gene transcription, which IL-1R2 showed an enhanced mRNA stability [ 123 ].

A condition termed deficiency of interleukin-1 antagonist (DIRA) in humans proves the importance of IL-1Ra for the regulation of IL-1β signaling. DIRA results in lethal sterile multi-organ inflammation if not treated with recombinant IL-1Ra [ 90 , 124 ]. Furthermore, a variable number of tandem repeats polymorphism in the IL-1Ra gene (IL-1RN) was shown to be associated with an increased risk to develop cancer [ 59 ]. Furthermore, a study showed that the synonymous coding variant rs315952 of IL-1RN is strongly correlated with improved survival after septic shock due to increased plasma levels of IL-1RA [ 125 ].

IL-1R2 exists as a membrane-bound and as a soluble form. Both can bind both IL-1α and IL-1β, with higher affinity to IL-1β, and inhibit the IL-1 signaling cascade by preventing both cytokines from binding to IL-1R1 [ 90 , 126 , 127 ]. The soluble form of IL-1R2 is either generated through proteolytic cleavage of the extracellular region [ 94 , 128 , 129 , 130 , 131 ] or by alternative splicing [ 101 , 132 , 133 ]. Both IL-1Ra and IL-1R2 regulate IL-1 signaling by different mechanisms, and thereby reduce IL-1-mediated inflammation [ 9 ].

IL-1R2 was shown to play important roles in several diseases such as diabetes, atherosclerosis, sepsis, Alzheimer’s disease, autoimmune inner ear disease (AIED), ulcerative colitis, and arthritis [ 134 ]. AIED patients do not express the full length and thereby functional IL-1R2 in their peripheral blood cells which suggests a protective function of IL-1R2 in AIED [ 135 ]. A recent study by Mora-Buch and coworkers showed that IL-1R2 production by epithelial cells was increased during remission of ulcerative colitis [ 136 ]. These results were confirmed by the finding that IL-1R2 transcription was reduced in patients that relapsed within 1 year compared to patients in remission. In addition, Shimizu and coworkers identified IL-R2 as an important regulator of arthritis. IL-1R2 inhibits collagen-induced arthritis by downregulation of the IL-1 signaling cascade in macrophages [ 95 ].

4. Role of IL-1 in Inflammation

IL-1 was early identified as an important hematopoietic factor that induced expression of colony stimulating factors on progenitor cells as well as leukocytes and stroma cells [ 137 ]. In line, administration of IL-1 to lethally irradiated mice resulted in recovery of the myeloid compartment [ 138 ].

IL-1 has been strongly implicated in the inflammatory response of immune cells due to its pronounced IKK [ 139 ] and MEK [ 140 ] stimulatory effects including upregulation of MyD88 [ 141 ]. In this regard, IL-1 constitutes a potent stimulator of APC as initially described by Koide and coworkers using recombinant IL-1α for murine splenic DC [ 142 ], and confirmed by Heufler and coworkers identifying IL-1β as the relevant factor for the maturation of Langerhans cells [ 143 ] that constitute the epidermal DC population. Furthermore, IL-1β was shown to promote the differentiation of monocytes to conventional DC [ 139 ] and to M1-like macrophages [ 144 ]. In addition, IL-1 was early demonstrated to support the proliferation of activated B cells and their differentiation to plasma cells [ 145 ]. IL-1 in combination with IL-2 promoted the expansion of natural killer (NK) cells as well as of CD4 + CD8 + T cells [ 146 ]. Moreover, IL-1β generated by activated APC induced type 1 immune responses. This was reflected by elevating frequencies of IFN-γ producing cytotoxic T lymphocytes (CTL) [ 147 ] and the polarization of αβ CD4 + T cells towards T helper cell type 1 (Th1) [ 148 ]. However, IL-1 was also reported to induce IL-4 receptor expression on CD4 + T cells [ 149 ] which is necessary for maintenance of Th2 cells. In combination with IL-6 [ 150 ] and IL-23 [ 151 ], IL-1β favored the differentiation of αβ CD4 + T cells towards Th17. Of note, IL-1β was described to counter-act TGF-β induced Foxp3 expression in CD4 + T cells, thereby inhibiting the differentiation of regulatory T cells (Treg) [ 152 ]. Moreover, IL-1β induced alternative splicing of Foxp3 in Treg resulting in a functional switch towards Th17 [ 153 ].

IL-1β not only promoted Th17 polarization via IL1R signaling, but also supported APC-induced Th17 production by CD4 + memory T cells. In this regard, human DC were reported to upregulate both surface-bound and soluble CD14 which interacted with T cell surface receptors promoting IL-17 production [ 154 ]. In the case of memory Th17 cells, IL-1β inhibited restimulation-induced IL-10 production [ 155 ]. Similar to αβ CD4 + T cells, IL-1 with IL-23 also induced IL-17 production by γδ CD4 + T cells [ 156 ].

IL-1 induced in the course of acute inflammation promoted the upregulation of adhesion receptors on immune and endothelia cells as a prerequisite for infiltration of leukocytes to sites of infection [ 157 ]. The key role of IL-1β in this regard was exemplified by Miller and coworkers demonstrating that neutrophil-mediated eradication of cutaneous S. aureus infection critically depended on IL-1 signaling [ 158 ].

Besides the beneficial role of IL-1β for clearance of infections, this cytokine has also been attributed to contribute to the severity of inflammatory diseases [ 124 , 159 ]. For example, elevated IL-1 signaling was demonstrated to cause neuronal cell death [ 160 ]. Of note, inflammasome activation and hence elevated IL-1β production has been observed in patients suffering from epilepsy [ 161 ], stroke [ 162 ], Alzheimer’s disease [ 163 ], and other neurological disorders [ 164 ]. IL-1 is also an important mediator of autoimmune diseases as evidenced by the therapeutic efficacy of IL-1Ra or IL-1β specific antibodies for treatment of rheumatoid arthritis [ 159 ] and gouty arthritis [ 165 ]. Autoreactive T cells are a central component of autoimmune diseases [ 166 ], and (myeloid) cells that generate IL-1 contribute to disease progression [ 167 ]. In contrast, so-called autoinflammatory diseases are largely caused by dysregulated IL-1β production [ 1 ]. As described above, hereditary gain-of-mutations in inflammasome components are causative for diseases such as CAPS (see Section 2.2.1 ) that are also treated by IL-1 signaling inhibition. Overproduction of IL-1β has also been observed in case of type 2 diabetes. Glucose itself induced NF-κB activity and hence IL-1β expression in β cells [ 168 ]. Furthermore, minimally oxidized low density lipoproteins were found to be elevated in diabetic patients which triggered IL-1β gene expression via TLR4 engagement [ 169 ]. In the same study, accumulation of islet amyloid polypeptide was shown to mediate NLRP3 inflammasome activation in islet macrophages [ 170 ]. In general, IL-1β mediated destruction of pancreatic β islet cells which was counteracted in patients by administration of IL-1Ra [ 171 ].

5. Role of IL-1β in Tumor Development

Proinflammatory innate cytokines including IL-1, TNF-α, and IL-6 are crucial to resolve acute inflammations. However, high levels of innate cytokines as apparent in chronic inflammation may promote tumor development by driving sustained NF-κB activation [ 172 ] and mitogen activated protein kinase (MAPK) activity [ 173 ]. Moreover, these cytokines promote expression of pro-tumorigenic genes that encode cell cycle, antiapoptotic and other proteins. Additional signaling pathways including protein kinase B (AKT) or Wingless (WNT) have been attributed tumor-inducing properties [ 174 ].

The development of multiple myeloma constitutes one example of a direct link between aberrant IL-1 production and tumor induction. Multiple myeloma is characterized by an accumulation of monoclonal plasma cells [ 175 ]. Smoldering multiple myeloma constitutes an early stage of multiple myeloma as patients develop the disease within one to two years later [ 176 ]. The driving mechanism is high level production of IL-1β by plasma cells which induces IL-6 in stromal cells [ 177 ]. IL-6 in turn promotes the development of malign plasma cells. Treatment of patients expected to develop multiple myeloma with IL-1Ra and the glucocorticoid dexamethasone proved successful to prevent further disease progression [ 178 ].

5.1. Anti-Tumorigenic Effects of IL-1β

In agreement with the importance of IL-1 for the induction of type 1 and type 17 antigen-specific T cell responses, the potential of recombinant IL-1 to induce pronounced anti-tumorigenic effects has early been assessed. For example, Nakamura and coworkers [ 179 ] demonstrated that intratumoral injection of IL-1a resulted in regression of different types of transplanted syngeneic tumors, including sarcoma, melanoma, and adenocarcinoma. North and colleagues [ 180 ] observed tumor regression only when IL-1 was applied intratumorally to tumors that had grown for a week, but not at earlier timer points. Due to the finding that T cell-depleted mice showed no signs of IL-1 induced tumor regression, the authors suggested that IL-1 was critical for the expansion of tumor antigen-specific T cells. Besides these therapeutic effects, Allen and coworkers [ 181 ] demonstrated a protective role of IL-1β in mouse models of chemically induced colitis and colon carcinoma. In myeloma-resistant T cell receptor (TCR)-transgenic severe combined immunodeficiency (SCID) mice [ 182 ] injected with myeloma cells, in vivo neutralization of IL-1 resulted in a decreased production of IFN-γ by tumor-specific Th1 cells and attenuated infiltration of macrophages and tumor growth [ 183 ].

While application of recombinant IL-1 exerted anti-tumor effects in a number of mouse studies (see above), in several clinical trials systemic application of IL-1 yielded only poor effects on hematopoiesis and tumor development, but significant toxicity [ 184 ]. To prevent widespread cytotoxicity, but to promote APC activation, IL-1 was encapsulated into microspheres [ 185 ]. These IL-1 loaded microspheres were preferentially internalized by macrophages [ 186 ]. Intratumoral application of such IL-1 delivery systems into fibrosarcoma-burdened mice delayed tumor growth which was associated with tumor cell necrosis and strong infiltration of leukocytes.

Tumor cell necrosis resulting from pronounced type 1 [ 187 ] and type 17 [ 188 ] immune responses and from chemotherapy [ 189 ] may further support the IL-1 signaling cascade by the release of mitochondrial ATP [ 190 ]. Extracellular ATP binds the purinergic receptor P2RX7 and thereby stimulates the NLRP3 inflammasome of myeloid APC [ 191 ]. Accordingly, mice deficient for NLRP3 inflammasome activation and IL-1 and IL-17 signaling [ 192 ] showed no response to chemotherapy with immunogenic cell death inducers such as anthracyclines. On cellular level, DC that lacked inflammasome activity when incubated with dying tumor cells that released ATP as a NLRP3 inflammasome inducer were no efficient CTL inducers [ 191 ]. Moreover, in anthracycline-treated breast cancer patients, an association between the occurrence of an allele of the P2RX7 receptor with reduced binding affinity to ATP and the beneficial effect of chemotherapy was observed. In contrast to these examples of anti-tumor effects of IL-1β, a pro-tumorigenic role of this cytokine has been demonstrated in numerous studies, which is outlined below.

5.2. Tumor-Promoting Effects of IL-1β

IL-1 plays a key role in carcinogenesis and tumor growth [ 193 ], due to its importance as a key downstream mediator of inflammation [ 194 ]. Increased levels of IL-1β in body fluids are correlated in experimental tumor models and in cancer patients with bad prognosis, carcinogenesis and invasiveness of the tumor [ 195 , 196 , 197 ]. The key mechanisms by which IL-1β promotes tumor development are driving chronic non-resolved inflammation [ 193 ], endothelial cell activation [ 194 ], tumor angiogenesis [ 195 ] and induction of immunosuppressive cells ( Figure 3 ). Altogether, these mechanisms account for suppression of the adaptive immunity, tumor promotion and metastasis [ 193 ].

5.2.1. Tumor Development Caused by Chronic Inflammation

By now, chronic inflammation is recognized as one of the hallmarks in carcinogenesis, tumor progression, and metastasis [ 198 , 199 ]. Chronic inflammation results from the inability of the body to resolve an acute inflammatory response. Persistent inflammation can trigger the development of various tumors such as colorectal cancer, gastric cancer, mucosa-associated lymphoid tissue cancer, lung cancer, bladder cancer, and HCC [ 200 , 201 , 202 ]. Hepatic inflammation for example as induced by hepatitis C virus infection is a cytokine driven disease, especially via IL-1β, triggering the transition from non-alcoholic fatty liver disease to severe fibrogenesis, and finally hepatocellular carcinoma [ 203 ]. IL-1β is induced by a Helicobacter pylori infection, the most common chronic bacterial infection, and is the etiological agent for gastric cancer [ 204 ]. The association of gastritis and gastric tumor development has been shown to be strongly associated with genetic polymorphisms in the IL-1β locus [ 205 ]. IL-1β therefore enhances the number of gastric tumors [ 206 ]. Another significant mechanistic link between IL-1β and an increased risk of gastric cancer is the induction of aberrant DNA methylation via this interleukin [ 207 ]. IL-1β is also about 2–3-fold upregulated in small airway epithelial cells of chronic obstructive pulmonary disease (COPD) patients and seems to influence COPD airway inflammation [ 202 ]. Because COPD is a known risk factor for developing lung cancer [ 208 ], IL-1β seems to play a profound role in this regard as well. Additionally, the development and invasiveness of tumors induced by the chemical carcinogen 3-methylcholanthrene (3MCA) is promoted by IL-1β [ 209 ]. Furthermore, the induction of immunosuppressive myeloid-derived suppressor cells (MDSC), regulatory T cells (Treg), tumor-associated macrophages (TAM) [ 210 ] and NK cells [ 211 ] is a consequence of chronic inflammation. Altogether, IL-1β plays a major role already in the transition of chronic inflammation to tumor induction.

5.2.2. Tumor Microenvironment

Immunosuppression

The tumor microenvironment is characterized by dominant immunosuppression. It is induced by myeloid regulatory cells such as neutrophils [ 212 , 213 ], TAM [ 214 , 215 , 216 ], MDSC [ 217 , 218 , 219 , 220 ], and regulatory DC [ 221 , 222 ]. In addition, Treg and carcinoma-associated fibroblasts (CAF) contribute to the immunosuppressive milieu [ 222 , 223 , 224 , 225 ]. In a head and neck squamous cell carcinoma (HNSCC) mouse model inflammasome activation and thereby IL-1β upregulation was shown to cause an insufficient anti-tumor reactivity via the immunosuppressive network of MDSC, TAM and Treg [ 226 ]. MDSC and Treg have also been illustrated to be key negative regulators of the immune system in melanoma patients [ 227 , 228 , 229 ].

TAM

Macrophages particularly populate the tumor microenvironment and are highly prevalent in inflammation-mediated tumors. These cells are called alternatively activated (M2) macrophages [ 174 , 230 ]. In general, macrophages that infiltrate tumor tissues are driven by tumor-and T cell-derived cytokines to acquire a polarized M2 phenotype characterized by production of IL-4, IL-13, IL-10, and glucocorticoid hormones [ 227 , 231 ]. These mediators influence all aspects of tumor growth and progression, providing a nurturing niche for cancer stem cells, and promoting angiogenesis, e.g., by IL-1β, dependently expressed vascular endothelial growth factor (VEGF), paving the way for metastasis, and taming adaptive immune response [ 193 , 216 ].

The sabotage of anti-tumor immunity is achieved by impairing T cell activation and by inhibiting M1 macrophage-mediated innate anti-tumor immune responses [ 227 ]. TAM provide an inflammatory microenvironment via inflammasome activation and IL-1β production which promotes, for example, breast cancer progression [ 232 ]. IL-1β induces CCL2 expression in TAM and tumor cells as well, regulating myeloid cell recruitment into tumor tissue [ 232 , 233 ].

MDSC

MDSC are a heterogeneous population of immature myeloid cells that are precursors of DC, macrophages, and granulocytes [ 234 ]. They are induced by tumor-derived soluble factors [ 235 ]. IL-1β is a tumor-associated factor leading to expansion and migration of MDSC, being regulated by the IL-1RI/NF-κB pathway [ 236 ]. MDSC accumulate in the blood, lymph nodes, bone marrow and at tumor sites in most patients and in tumor-burdened animals. These cells downregulate immune surveillance and antitumor immunity by multiple mechanisms, thereby facilitating tumor growth [ 227 , 234 , 237 , 238 , 239 , 240 , 241 , 242 , 243 ].

It could be shown that mice injected with 4T1 mammary carcinoma tumor cells transfected with an IL-1β expression vector propagated significantly higher levels of MDSC compared to mice carrying the same tumors but not secreting IL-1β [ 244 ]. Furthermore, the number of monocytic (mo-)MDSC was significantly increased in the prematastatic lungs of tumor-bearing mice, thus promoting tumor cell arrest on endothelial cells and metastasis [ 245 ]. The translational importance of IL-1β as a driver of MDSC propagation is underlined by the finding that in peripheral blood of advanced melanoma patients an increased level of serum IL-1β was associated with the frequency of mo-MDSC and Treg. An enrichment of circulating mo-MDSC significantly correlated with decreased progression-free survival of melanoma patients [ 246 ]. Furthermore, IL-1β upregulated cyclooxygenase-2 (COX-2), which encodes prostaglandins that mediate MDSC propagation [ 247 ]. MDSC produce IL-1β and other pro-inflammatory molecules activating tissue-resident endothelial cells to produce VEGF and other angiogenic factors [ 248 ]. These proangiogenic factors induced endothelial cell proliferation and blood vessel formation. Besides direct effects of IL-1β and products of its target genes on the expansion of the MDSC pool, IL-1β induced CC-chemokine ligand 2 (CCL2) in macrophages and tumor cells. Elevated CCL2 within the tumor microenvironment promoted the recruitment of C-C chemokine receptor type 2 expressing (CCR2 + ) myeloid cell types, including MDSC and TAM [ 232 ].

Furthermore, IL-1β promotes cancer cell adhesion and hepatic metastases by up-regulation of vascular cell adhesion molecule (VCAM-1) on hepatic sinusoidal endothelium [ 249 , 250 ]. It was also revealed, that IL-1β expression in lungs of melanoma-bearing mice is facilitated by lung-recruited mo-MDSC, resulting in enhanced E-selectin expression [ 245 ].

CAF

Another key player within the tumor microenvironment is the group of carcinoma-associated fibroblasts (CAF) which contribute to the growth, expansion, and dissemination of cancer cells [ 251 ]. CAF originate from the activation of resident fibroblasts or a wide spectrum of other precursor cells such as smooth muscle cells, bone marrow-derived mesenchymal stem cells, epithelial cells, carcinoma cells, and many more [ 252 , 253 ]. CAF activation is triggered by a variety of stimuli, including cancer cell-derived TGF-β1 (tumor growth factor-β1), PDGF (platelet-derived growth factor)α, PDGFβ, basic fibroblast growth factor (bFGF), and IL-6 [ 254 ]. CAF contribute to the malignant aggressiveness of tumors through the induction of pro-inflammatory factors including IL-1β, IL-6/8, CCL2, CXCL (C-X-C motif ligand) 1/2/3/12, COX-2, osteopontin (OPN), and intercellular adhesion molecule 1 (ICAM-1) [ 225 , 251 ]. IL-1β was also identified as a stromal-acting chemokine secreted by ovarian cancer cells, suppressing p53 protein expression in CAF. p53 is known to maintain genomic integrity through apoptosis regulation despite DNA damage or instability and also regulates inflammation [ 255 ]. Knockdown of p53 expression significantly enhanced the expression and secretion of chemokines IL-1β, IL-6, IL-8, growth regulated oncogene-alpha (GRO-α), and VEGF. In vivo, a significant increase in mouse xenograft ovarian cancer tumor was seen as well [ 256 ]. Thereby, epithelial cancer cells use IL-1β as a communication factor to generate a pro-tumorigenic inflammatory microenvironment [ 256 ]. Liver metastasis of colorectal cancer is promoted by recruiting circulating CAF to facilitate prophase tumor construction tumorigenicity via an elevated expression of structural maintenance of chromosomes 1A (SMC1A), a subunit of cohesin [ 257 ]. Furthermore, it was demonstrated that signaling mediated by the G protein estrogen receptor (GPER) cells, induced by estrogen, triggered IL-1β and IL-1R1 expression in CAF and in breast cancer cells. Thus, the ligand-activated GPER triggers the Epidermal Growth Factor Receptor (EGFR)/extracellular signal–regulated kinases(ERK)/PKC signaling transduction pathway generating a feed forward loop that couples IL-1β induction by CAF to IL-1R1 expression by cancer cells [ 258 ]. This resulted in an up-regulation of IL-1β/IL1R1 target genes such as PTGES (prostaglandin E synthase), COX2, RAGE (receptor for advanced glycation endproducts), and ABCG2 (ATP binding cassette subfamily G member 2). Thereby, regulatory interaction between CAF and the cancer cells induces migration and invasive features in breast cancer cells via alterations of fibroblastoid cytoarchitecture and F-actin reorganization [ 258 ].

5.2.3. Angiogenesis

IL-1β promotes tumor development as well by influencing angiogenesis. Tumor growth requires the sprouting of new capillaries from preexisting blood vessel. Microscopic in situ lesions of a tumor may exist for years without having their own microcirculation. For tumor progression, an angiogenic switch permits rapid growth and invasion [ 259 , 260 ]. It was shown that microenvironmental IL-1β leads to in vivo angiogenesis and invasiveness of different tumor cells [ 260 ]. Confirming these results, IL-1β secreting tumors showed enhanced tumor angiogenesis as evidenced by highly increased secretion of VEGF by malignant cells and blood vessel density in tumors [ 222 , 261 , 262 ]. In the early angiogenic response during tumor development, cross talk between VEGF and IL-1β takes place. IL-1β and VEGF seem to induce each other and are both essential for blood vessel growth. Furthermore, IL-1β induced CCL2 expression in macrophages and tumor cells [ 232 ]. CCL2 has been shown to have multiple pro-tumorigenic functions such as mediating tumor growth and angiogenesis [ 233 ].

5.2.4. Metastasis

IL-1β paves the way for tumor induction and growth as well as metastasis. Tumor metastasis is a complex process, including: (i) tumor cell dissemination from primary foci; (ii) their infiltration into the vascular system; (iii) transition through the circulation; (iv) capture in capillary beds; and (v) formation of metastatic nodules in distant target organs [ 263 ]. In the process of tumor metastasis, the construction of a pre-metastatic microenvironment is an essential step. The environment of the distant metastatic target organs are rebuilt prior to the arrival of the tumor cells from the primary foci [ 264 ]. It could be shown that the number of mo-MDSC is significantly increased in the lungs of melanoma-burdened mice before the arrival of tumor cells. These MDSC secreted IL-1β, resulting in the expression of E-selectin in endothelia cells, being attributed to increased distant metastasis in the lung [ 245 ]. Primary tumor cells enable a distant engraftment by secretion of different growth factors [ 265 ], resulting in chemokine and cytokine upregulation in the metastatic targeted organ. In primary and metastatic tumor tissue, elevated levels of IL-1β could be found [ 232 ]. Furthermore, an augmentation of lung metastasis from A375M tumor cells could be observed after (IV) injection of IL-1β [ 266 ]. Upregulated expression of proinflammatory chemokines and cytokines resulted in recruitment of bone marrow-derived hematopoietic cells [ 267 ]. Mo-MDSC are a significant component of these recruited cells [ 245 ].

In experimental studies, NLRP3 and thereby IL-1β expression levels were correlated with the tumor size and the metastatic status of the sentinel lymph node [ 268 ]. IL-1β levels were also shown to correlate with implantation and liver metastatic growth in a melanoma model [ 269 , 270 ]. Intravenous application of IL-1β enhanced the hepatic metastasizing ability of intrasplenically injected B16 melanoma cells [ 270 ]. IL-1β and TNFα induced IL-18 release upregulating the expression of VCAM-1 on hepatic sinusoidal endothelium (HSE) and thereby promoting cancer cell adhesion and liver metastases [ 249 ]. An IL-1β dependent upregulation of VCAM-1 by HSE, accompanied by elevated expression of the very late antigen-4 (VLA-4) could also be confirmed in another study. Hereby, adhesion of the melanoma cells to HSE cells take place leading to an increased metastasis [ 271 ].

6. Anti-Cancer Agents Induce IL-1β

Chemotherapy causes numerous undesirable symptoms affecting physical functioning and quality of life. An association between cancer treatment-related symptoms and inflammatory cytokines could be shown, triggered by increased production and synergistic action of IL-1β and TNFα [ 272 , 273 ]. IL-1β processing and secretion is induced by numerous chemotherapeutic drugs and has been shown to either elevate IL-1β gene expression or inflammasome activity in myeloid cells (summarized in Table 1 ).

Most recently, we have identified the clinically used B-Raf proto-oncogene, serine/threonine kinase (BRAF) V600E inhibitors (BRAFi) Dabrafenib (DAB) and Vemurafenib (VEM) to simultaneously mediate elevated IL-1β gene expression and inflammasome activation in DC and macrophages as an off target effect [ 6 ]. BRAFi are used for the treatment of metastatic melanoma in cases of a mutation in the signaling adaptor BRAF that results in ERK hyperactivation as an oncogenic target. This mutation (BRAF V600E ) can be found in about 40% of all melanomas. We observed that DAB strongly upregulated IL-1β production in unstimulated and LPS-stimulated myeloid mouse APC and in unstimulated human primary DC. VEM also enhanced IL-1β secretion by mouse DC and macrophages, but not in human DC. Both BRAFi activated the NLRC4 inflammasome, and DAB additionally induced caspase-8 activation for pro-IL-1β processing. Contrarily, the newly developed BRAFi Encorafenib (ENC) had no effect on IL-1β production ( Figure 4 ). The recently conducted phase III study for applying ENC plus the accordingly applied MEK1/2 inhibitor Binimetinib versus VEM or ENC administered alone showed improved progression-free survival and improved overall response of Encorafenib/Binimetinib treated patients. Treatment with ENC exerted less adverse events such as rash compared to VEM, although the frequency of grade 3 rash was slightly increased [ 274 ].

In our study on the IL-1β promoting effects of BRAFi, in the case of human primary DC isolated from peripheral blood, only a fraction of samples responded to DAB treatment with an induction of IL-1β [ 254 ]. These results are in line with the clinically observed side effect of DAB to cause fever in about 40–50% of patients treated with that BRAFi [ 275 ] which could be mediated by induced IL-1β due to its pronounced pyrogenic effects. Thus, these results suggest that genetic polymorphisms within the IL-1β or inflammasome genes determine the occurrence of these immunmodulatory off target effects of DAB.

The observation that chemotherapeutics may increase IL-1β levels in tumor patients may be detrimental for tumor therapy and therefore needs to be taken into consideration. Westborn et al. showed that treatment of SCID mice and Hmeso cells with the IL-1β inducing chemotherapeutic doxorubicin in combination with IL-1Ra resulted in a smaller tumor size compared to single cisplatin or IL-1Ra treatment [ 276 ]. Applying IL-1Ra in combination with cytotoxic chemotherapy seems such as a potential targeting option to reduce IL-1β dependent side effect of chemotherapeutic treatment. Furthermore, BRAFi treatment-induced tolerance in melanoma could be shown to result from a cytokine-signaling network involving TAM-derived IL-1β and CAFs derived C-X-C motif chemokine receptor 2 (CXCR2) ligands. The loss of host IL-1R signaling reduced melanoma growth in vivo as well [ 277 ]. These results could be confirmed in another study issuing the outcome of breast and lung carcinoma treatment with paclitaxel in combination with Anakinra. This combination treatment resulted in a reduced tumor burden. However, the combined therapy increased metastasis in mice lungs when compared to a monotherapy with paclitaxel. Thus, dual effects of blocking the IL1 pathway on tumor growth are possible. Therefore, treatments using “add-on” drugs such as the IL-1β blocker to conventional chemotherapy should be investigated in appropriate tumor models monitoring both the primary tumor and the induction of metastases [ 278 ].

7. Inhibition of IL-1 Signaling Inhibits Tumor Growth

7.1. Genetic Models

Chronic high-level expression of bioactive IL-1β is an important promotor of tumor development [ 209 ]. IL-1β is involved in the positive feedback loop of IL-1β/Akt/retinoic acid receptor α (RARα) signaling, and thereby transmits the oncogenic property of RARα in gastric carcinoma [ 279 ]. In transgenic mice the expression of human IL-1β induced spontaneous gastric cancer, correlating with early recruitment of MDSC to the stomach [ 236 ]. H. pylori infection was also shown to induce IL-1β production which played a crucial role in gastric inflammation. IL-1R1 deficient mice demonstrated attenuated infiltration of inflammatory cells, especially of macrophages and neutrophils, into the stomach of H. pylori infected animals compared with wild type (WT) mice [ 280 ]. Furthermore, reduced susceptibility to gastric carcinogenesis could be observed in IL-1R1 -/- mice. Similarly, IL-1β -/- mice were characterized by a reduction of H. pylori induced gastric tumors [ 206 ].

IL-1β was reported to induce methylation-dependent gene silencing via nitric oxide (NO) production [ 280 ]. NO-induced aberrant DNA methylation is one of the major inactivating mechanisms of tumor suppressor genes. An absence of E-cadherin promotor methylation in IL-1R1 -/- mice was observed, therefore IL-1 induced methylation is likely to be one of the major mechanisms for chronic inflammation inducing cancer [ 206 , 280 ]. Therefore, gastric inflammation is considered as an inducer of DNA methylation and as a driving force in gastric carcinogenesis.

Additionally, IL-1β driven chronic Inflammation promoted the development and invasiveness of chemical carcinogen-induced tumors as well [ 196 , 260 ]. Mice deficient for IL-1β or IL-1R1 were protected against methylcholanthrene (MCA) carcinogenesis. At the site of carcinogen injection, a sparse leukocyte infiltration occurred in IL-1β deficient mice opposing the dense neutrophile infiltration in IL-1Ra -/- mice. In WT and IL-1α -/- mice leukocyte infiltration at this site was apparent being dominated by macrophages, whereas in the IL-1β -/- mice cellular infiltration was nearly absent [ 209 ].

Another important aspect of tumor growth being modulated and influenced by IL-1β knockout is the development of metastasis. In a breast cancer model, mice deficient for caspase-1 and thereby having reduced IL-1β levels exhibited significantly lower numbers of lung metastasis and attenuated tumor growth [ 232 ]. In a human oral squamous cell carcinoma (OSCC) model NLRP3 expression levels correlated with tumor size, lymph node metastatic status and IL-1β expression. Down-regulation of NLRP3 expression using short hairpin RNA markedly reduced IL-1β production and OSCC cell proliferation, migration and invasion. Moreover, silencing NLRP3 expression significantly inhibited OSCC tumor growth in vivo [ 268 ].

7.2. Pharmacological Inhibition

As outlined above, inhibition of IL-1β signaling by using appropriate mouse models was shown to influence multiple key mechanisms of tumor growth such as chronic inflammation that triggered tumor development [ 193 ], accumulation of immunosuppressive cells in the tumor milieu [ 194 ], angiogenesis [ 195 ] within the tumor microenvironment, and metastasis [ 196 ]. Therefore, blockade of IL-1β may constitute an important therapeutic rationale to impair tumor development and progression. Moreover, it may serve to reduce therapeutic side effects and for palliative care [ 289 ].

Several types of agents are available to prevent the biological activtiy of IL-1β, including IL-1β specific antibodies (Canakinumab) [ 290 ] and IL1Ra (Anakinra) [ 290 ] as well as inflammasome inhibitors (Thalidomide, Parthenolide, and BAY-11-7082) [ 260 , 289 , 291 ]. The two IL-1 blocking agents Anakinra and Canakinumab have already been approved for the treatment of systemic inflammatory disorders and display an excellent safety profile [ 290 ].

7.3. Immuno-Suppression

In the tumor microenvironment in HNSCC, impairment of T cell responses resulted in an immunosuppressive state which is caused by MDSC, Treg and TAM [ 292 , 293 ]. TAM and MDSC can be recruited to the tumor side by IL-1β [ 232 ]. In agreement, in a mouse breast cancer model inhibition of NLRP3 effectively reduced the tumor-resident population of MDCS [ 288 ] and TAM [ 232 ]. Similarly, in a HNSCC mouse model, a reduction of MDSC, Treg and TAM frequencies was achieved by blocking NLRP3 inflammasome activation using the specific inhibitor MCC950 [ 226 ]. Comparable effects were observed in murine and human breast cancer models when applying Anakinra. In these studies, blockade of IL-1 signaling was accompanied by a lower myeloid cell accumulation in the tumor microenvironment whereas normal inflammasome activity contrarily lead to the infiltration of MDSC and TAM into the microenvironment [ 232 ]. Furthermore, it could be shown, using the mouse mammary tumor virus (MMTV)—inducible fibroblast growth factor receptor 1 (iFGFR1) transgenic mouse model, that inhibition of IL-1β activity in vivo resulted in reduced iFGFR1 induced mammary epithelial proliferation and attenuated formation of hyperplasic structures. Targeting IL-1β partially inhibited formation of early-stage mammary lesions in part through the induction of Cox2 [ 294 ].

7.4. Angiogenesis

Without appropriate vascularization tumor cells become necrotic and/or apoptotic. In several studies, angiogenesis was assessed by the recruitment of blood vessel networks into Matrigel plugs containing tumor cells that were inoculated s.c. in mice. In case of IL-1β -/- mice, no vascularization of Matrigel plugs containing B16 melanoma cells occurred. Moreover, the incorporation of IL-1Ra to B16 containing plugs in WT mice inhibited the ingrowth of blood vessel networks into the plugs as well [ 260 ]. The necessity of IL-1β for angiogenesis and invasiveness of the tumor in vivo was also verified in DA/3 mammary and prostate cancer cell models [ 260 ].

VEGF and IL-1β were demonstrated to interact in an autocrine circuit using Matrigel plugs supplemented with B16 melanoma cells. IL-1β inhibition reduced tumor growth for an extended period. In contrast, specific VEGF neutralization initially resulted in an initial tumor inhibition, but followed by tumor recurrence [ 4 ]. Additionally, IL-1β was induced by leptin, leading to an increase in the expression of VEGF/VEGFR-2. Moreover, leptin upregulation of VEGF/VEGFR2 was partially mediated by IL-1 signaling [ 295 ]. This triad of cross talk among IL-1, VEGF, and leptin promoted angiogenesis in breast tumors. This interaction is an important driver of leptin-induced oncogenic action and a key link between obesity and cancer progression [ 296 ]. It could also be shown that NLRP3-dependent IL-1β promoted lymphangiogenesis by human macrophages via a S1P receptor 1(S1Pr1)-dependent pathway in vitro. The strong reduction of IL-1β in S1PR1 deficient TAM prevented lymphangiogenesis [ 297 ].

7.5. Metastasis

In a murine B16 melanoma metastasis model, intrasplenic injection of recombinant IL-1β or LPS increased experimental liver metastasis, while reduction of metastases and increased survival rates were observed following IL-1Ra treatment [ 269 , 270 ]. A similar outcome was confirmed in numerous studies in which exogenous IL-1Ra exerted an inhibitory effect of on lung and liver experimental metastasis of human and murine melanoma cells [ 249 , 250 , 291 ].

The results of the aforementioned studies led to the conclusion that inhibition of IL-1 signaling has a pronounced inhibitory effect on tumor growth by targeting different mechanisms of tumor development, such as: (i) reducing chronic inflammation which triggers tumor development; (ii) propagation of immune-suppressive cells; (iii) accumulation of regulatory cells in the tumor milieu; (iv) angiogenesis; and (v) metastasis.

8. Concluding Remarks

In the last decades, research has gathered a wealth of information on parameters that regulate IL-1β expression and on the multi-facetted role of IL-1β in pathophysiological conditions. IL-1β promotes APC-stimulatory activity and the upregulation of adhesion receptors on immune and endothelial cells as a prerequisite for the infiltration of leukocytes to sites of infection in acute inflammation. As a consequence of gain-of-function mutations of IL-1 expression regulating components, IL-1β is a driver of autoinflammatory diseases.

However, conflicting effects of IL-1β in terms of tumor development have been observed. Due to the induction of type 1 and type 17 antigen-specific T cell responses IL-1β exerts anti-tumorigenic effects. Contrarily, IL-1β within the tumor microenvironment can promote carcinogenesis, tumor growth, and metastasis by different key mechanisms such as driving chronic non-resolved inflammation, endothelial cell activation, tumor angiogenesis, and the induction of immune-suppressive cells. Clinically, a correlation between high levels of IL-1β and bad prognosis in cancer patients was observed. Therefore, numerous studies on IL-1β and its inhibition in animal and human tumor models were conducted. IL-1 signaling (Anakinra), and more specifically IL-1β (antibody-mediated) inhibition hereby seem to target key components of tumor development in most cases resulting in reduced tumor development.

Several drugs used for cancer treatment were shown to induce IL-1β production, which may lead to unwanted side effects. A combination of these drugs with IL-1Ra or an IL-1β blocking antibody reduced side effects and smaller tumor growth. Another study, however, showed that chemotherapeutic treatment with an additional IL-1β inhibitor also reduced tumor growth, but increased metastasis. Therefore, treatments using “add-on” drugs that inhibit IL-1 signaling in combination with conventional therapy should be investigated in appropriate tumor models looking at the primary tumor site as well as metastasis.

Overall, latest data suggest that (additional) IL-1β inhibition in numerous tumor models is a promising therapeutic option. Further consistent research in experimental mouse models is needed to assess the efficacy of IL-1β blockade in combination with chemotherapeutics or other drug treatment such as immunotherapy. Although growing evidence confirms beneficial effects of IL-1 signaling inhibition in tumor therapy, surprisingly, it is not standard treatment yet, even though the FDA approved IL-1 blockers such as Anakinra and Canakinumab for treatment of systemic inflammatory disorders and both drugs show an excellent safety profile.

To potentially enhance the overall efficacy of anti-tumor drugs known to induce IL-1β, the efficacy of additional IL-1 signaling blockade needs to be evaluated in tumor therapy.

Funding

This research received intramural funding by the University Medical Center Mainz.

Conflicts of Interest

The authors declare no conflict of interest.

Abbreviations

References

1. Dinarello C.A. An expanding role for interleukin-1 blockade from gout to cancer Mol. Med. 2014 20 Suppl. 1 S43 S58 10.2119/molmed.2014.00232 25549233 PMC4374514

2. Garlanda C. Dinarello C.A. Mantovani A. The interleukin-1 family: Back to the future Immunity 2013 39 1003 1018 10.1016/j.immuni.2013.11.010 24332029 PMC3933951

3. Awad F. Assrawi E. Louvrier C. Jumeau C. Georgin-Lavialle S. Grateau G. Amselem S. Giurgea I. Karabina S.A. Inflammasome biology, molecular pathology and therapeutic implications Pharmacol. Ther. 2018 187 133 149 10.1016/j.pharmthera.2018.02.011 29466702

4. Rider P. Carmi Y. Voronov E. Apte R.N. Interleukin-1alpha Semin. Immunol. 2013 25 430 438 10.1016/j.smim.2013.10.005 24183701

5. Cordero M.D. Alcocer-Gomez E. Ryffel B. Gain of function mutation and inflammasome driven diseases in human and mouse models J. Autoimmun. 2018 91 13 22 10.1016/j.jaut.2018.03.002 29610014

6. Hajek E.K.F. Bent R. Haas K. Bast A. Steinmetz I. Tuettenberg A. Grabbe S. Bros M. Braf inhibitors stimulate inflammasome activation and interleukin 1 beta production in dendritic cells Oncotarget 2018 in press 10.18632/oncotarget.25511 29983861 PMC6033361

7. Sierakowski S. Kucharz E.J. Lightfoot R.W. Jr. Goodwin J.S. Interleukin-1-production by monocytes from patients with systemic lupus erythematosus Clin. Rheumatol. 1987 6 403 407 10.1007/BF02206840 3502083

8. Arend W.P. Gordon D.F. Wood W.M. Janson R.W. Joslin F.G. Jameel S. IL-1 beta production in cultured human monocytes is regulated at multiple levels J. Immunol. 1989 143 118 126 2471731

9. Palomo J. Dietrich D. Martin P. Palmer G. Gabay C. The interleukin (IL)-1 cytokine family—Balance between agonists and antagonists in inflammatory diseases Cytokine 2015 76 25 37 10.1016/j.cyto.2015.06.017 26185894

10. Auron P.E. Webb A.C. Interleukin-1: A gene expression system regulated at multiple levels Eur. Cytokine Netw. 1994 5 573 592 7727690

11. Kominato Y. Galson D. Waterman W.R. Webb A.C. Auron P.E. Monocyte expression of the human prointerleukin 1 beta gene (IL1B) is dependent on promoter sequences which bind the hematopoietic transcription factor Spi-1/PU.1 Mol. Cell. Biol. 1995 15 58 68 10.1128/MCB.15.1.59 7799967 PMC231908

12. Yang Z. Wara-Aswapati N. Chen C. Tsukada J. Auron P.E. NF-IL6 (C/EBPbeta) vigorously activates IL1b gene expression via a Spi-1 (PU.1) protein-protein tether J. Biol. Chem. 2000 275 21272 21277 10.1074/jbc.M000145200 10801783

13. Husmann M. Jehnichen P. Jahn B. Schlosshan D. Romahn E. Marx J. A novel sp-1 site in the human interleukin-1 beta promoter confers preferential transcriptional activity in keratinocytes Eur. J. Immunol. 1996 26 3008 3014 10.1002/eji.1830261228 8977297

14. Toda Y. Tsukada J. Misago M. Kominato Y. Auron P.E. Tanaka Y. Autocrine induction of the human pro-IL-1beta gene promoter by IL-1beta in monocytes J. Immunol. 2002 168 1984 1991 10.4049/jimmunol.168.4.1984 11823535

15. Narayanan K.B. Park H.H. Toll/interleukin-1 receptor (TIR) domain-mediated cellular signaling pathways Apoptosis 2015 20 196 209 10.1007/s10495-014-1073-1 25563856

16. Lu Y.C. Kim I. Lye E. Shen F. Suzuki N. Suzuki S. Gerondakis S. Akira S. Gaffen S.L. Yeh W.C. Differential role for c-rel and c/ebpbeta/delta in tlr-mediated induction of proinflammatory cytokines J. Immunol. 2009 182 7212 7221 10.4049/jimmunol.0802971 19454718 PMC2805849

17. Zhang Y. Rom W.N. Regulation of the interleukin-1 beta (IL-1 beta) gene by mycobacterial components and lipopolysaccharide is mediated by two nuclear factor-IL6 motifs Mol. Cell. Biol. 1993 13 3831 3837 10.1128/MCB.13.6.3831 7684503 PMC359872

18. Godambe S.A. Chaplin D.D. Takova T. Bellone C.J. Upstream nfil-6-like site located within a dnase i hypersensitivity region mediates lps-induced transcription of the murine interleukin-1 beta gene J. Immunol. 1994 153 143 152 8207231

19. Pilzweger C. Holdenrieder S. Circulating hmgb1 and rage as clinical biomarkers in malignant and autoimmune diseases Diagnostics (Basel) 2015 5 219 253 10.3390/diagnostics5020219 26854151 PMC4665591

20. Mouri F. Tsukada J. Mizobe T. Higashi T. Yoshida Y. Minami Y. Izumi H. Kominato Y. Kohno K. Tanaka Y. Intracellular HMGB1 transactivates the human IL1b gene promoter through association with an ets transcription factor PU.1 Eur. J. Haematol. 2008 80 10 19 10.1111/j.1600-0609.2007.00981.x 18173740

21. Liu J. Yang T. Liu Y. Zhang H. Wang K. Liu M. Chen G. Xiao X. Kruppel-like factor 4 inhibits the expression of interleukin-1 beta in lipopolysaccharide-induced raw264.7 macrophages FEBS Lett. 2012 586 834 840 10.1016/j.febslet.2012.02.003 22449968

22. Cogswell J.P. Godlevski M.M. Wisely G.B. Clay W.C. Leesnitzer L.M. Ways J.P. Gray J.G. NF-kappa B regulates IL-1 beta transcription through a consensus NF-kappa B binding site and a nonconsensus CRE-like site J. Immunol. 1994 153 712 723 8021507

23. Roshan M.H. Tambo A. Pace N.P. The role of TLR2, TLR4, and TLR9 in the pathogenesis of atherosclerosis Int. J. Inflam. 2016 2016 1532832 10.1155/2016/1532832 27795867 PMC5067326

24. Brochu C. Cabrita M.A. Melanson B.D. Hamill J.D. Lau R. Pratt M.A. McKay B.C. NF-kappab-dependent role for cold-inducible RNA binding protein in regulating interleukin 1beta PLoS ONE 2013 8 e57426 10.1371/journal.pone.0057426 23437386 PMC3578848

25. Lebedeva T.V. Singh A.K. Constitutive activity of the murine IL-1 beta promoter is regulated by a transcriptional repressor Biochim. Biophys. Acta 1997 1353 32 38 10.1016/S0167-4781(97)00040-7 9256062

26. Zhang G. Zhang L. Duff G.W. A negative regulatory region containing a glucocorticosteroid response element (nGRE) in the human interleukin-1beta gene DNA Cell. Biol. 1997 16 145 152 10.1089/dna.1997.16.145 9052735

27. Ratman D. Vanden Berghe W. Dejager L. Libert C. Tavernier J. Beck I.M. De Bosscher K. How glucocorticoid receptors modulate the activity of other transcription factors: A scope beyond tethering Mol. Cell. Endocrinol. 2013 380 41 54 10.1016/j.mce.2012.12.014 23267834

28. Talwar H. Bauerfeld C. Bouhamdan M. Farshi P. Liu Y. Samavati L. MKP-1 negatively regulates LPS-mediated IL-1beta production through p38 activation and HIF-1alpha expression Cell. Signal. 2017 34 1 10 10.1016/j.cellsig.2017.02.018 28238855 PMC5410178

29. Zhang W. Petrovic J.M. Callaghan D. Jones A. Cui H. Howlett C. Stanimirovic D. Evidence that hypoxia-inducible factor-1 (HIF-1) mediates transcriptional activation of interleukin-1beta (IL-1beta) in astrocyte cultures J. Neuroimmunol. 2006 174 63 73 10.1016/j.jneuroim.2006.01.014 16504308

30. Blouin C.C. Page E.L. Soucy G.M. Richard D.E. Hypoxic gene activation by lipopolysaccharide in macrophages: Implication of hypoxia-inducible factor 1alpha Blood 2004 103 1124 1130 10.1182/blood-2003-07-2427 14525767

31. Liang M.D. Zhang Y. McDevit D. Marecki S. Nikolajczyk B.S. The interleukin-1beta gene is transcribed from a poised promoter architecture in monocytes J. Biol. Chem. 2006 281 9227 9237 10.1074/jbc.M510700200 16439360

32. Marecki S. Riendeau C.J. Liang M.D. Fenton M.J. PU.1 and multiple IFN regulatory factor proteins synergize to mediate transcriptional activation of the human IL-1 beta gene J. Immunol. 2001 166 6829 6838 10.4049/jimmunol.166.11.6829 11359842

33. Gray J.G. Chandra G. Clay W.C. Stinnett S.W. Haneline S.A. Lorenz J.J. Patel I.R. Wisely G.B. Furdon P.J. Taylor J.D. A CRE/ATF-like site in the upstream regulatory sequence of the human interleukin 1 beta gene is necessary for induction in U937 and THP-1 monocytic cell lines Mol. Cell. Biol. 1993 13 6678 6689 10.1128/MCB.13.11.6678 8413264 PMC364731

34. Willis S.A. Nisen P.D. Inhibition of lipopolysaccharide-induced IL-1 beta transcription by cyclic adenosine monophosphate in human astrocytic cells J. Immunol. 1995 154 1399 1406 7822806

35. Roman J. Ritzenthaler J.D. Perez R.L. Roser S.L. Differential modes of regulation of interleukin-1beta expression by extracellular matrices Immunology 1999 98 228 237 10.1046/j.1365-2567.1999.00866.x 10540221 PMC2326922

36. Roman J. Ritzenthaler J.D. Fenton M.J. Roser S. Schuyler W. Transcriptional regulation of the human interleukin 1beta gene by fibronectin: Role of protein kinase C and activator protein 1 (AP-1) Cytokine 2000 12 1581 1596 10.1006/cyto.2000.0759 11052809

37. Loegering D.J. Lennartz M.R. Protein kinase C and toll-like receptor signaling Enzyme Res. 2011 2011 537821 10.4061/2011/537821 21876792 PMC3162977

38. Wu T.T. Tai Y.T. Cherng Y.G. Chen T.G. Lin C.J. Chen T.L. Chang H.C. Chen R.M. GATA-2 transduces LPS-induced IL-1beta gene expression in macrophages via a toll-like receptor 4/MD88/MAPK-dependent mechanism PLoS ONE 2013 8 e72404 23940812 10.1371/journal.pone.0072404 PMC3735524

39. Wessels I. Fleischer D. Rink L. Uciechowski P. Changes in chromatin structure and methylation of the human interleukin-1beta gene during monopoiesis Immunology 2010 130 410 417 10.1111/j.1365-2567.2009.03243.x 20141541 PMC2913220

40. Yoza B.K. McCall C.E. Facultative heterochromatin formation at the IL-1 beta promoter in LPS tolerance and sepsis Cytokine 2011 53 145 152 10.1016/j.cyto.2010.10.007 21078560 PMC3021647

41. Chen H. Wilkins L.M. Aziz N. Cannings C. Wyllie D.H. Bingle C. Rogus J. Beck J.D. Offenbacher S. Cork M.J. Single nucleotide polymorphisms in the human interleukin-1b gene affect transcription according to haplotype context Hum. Mol. Genet. 2006 15 519 529 10.1093/hmg/ddi469 16399797

42. Landvik N.E. Tekpli X. Anmarkrud K.H. Haugen A. Zienolddiny S. Molecular characterization of a cancer-related single nucleotide polymorphism in the pro-inflammatory interleukin-1b gene Mol. Carcinog. 2012 51 Suppl. 1 E168 E175 10.1002/mc.21910 22467534

43. Gordon S. Akopyan G. Garban H. Bonavida B. Transcription factor YY1: Structure, function, and therapeutic implications in cancer biology Oncogene 2006 25 1125 1142 10.1038/sj.onc.1209080 16314846

44. Zhang G. Zhou B. Li S. Yue J. Yang H. Wen Y. Zhan S. Wang W. Liao M. Zhang M. Allele-specific induction of IL-1beta expression by c/ebpbeta and PU.1 contributes to increased tuberculosis susceptibility PLoS Pathog. 2014 10 e1004426 10.1371/journal.ppat.1004426 25329476 PMC4199770

45. Yin Y. Liu Y. Pan X. Chen R. Li P. Wu H.J. Zhao Z.Q. Li Y.P. Huang L.Q. Zhuang J.H. Interleukin-1beta promoter polymorphism enhances the risk of sleep disturbance in Alzheimer’s disease PLoS ONE 2016 11 e0149945 26937653 10.1371/journal.pone.0149945 PMC4777499

46. Cubino N. Montilla C. Usategui-Martin R. Cieza-Borrela C. Carranco T. Calero-Paniagua I. Quesada A. Canete J.D. Queiro R. Sanchez M.D. Association of IL1beta (-511 A/C) and il6 (-174 G > C) polymorphisms with higher disease activity and clinical pattern of psoriatic arthritis Clin. Rheumatol. 2016 35 1789 1794 10.1007/s10067-016-3301-2 27188858

47. Tayel S.I. Fouda E.A.M. Elshayeb E.I. Eldakamawy A.R.A. El-Kousy S.M. Biochemical and molecular study on interleukin-1beta gene expression and relation of single nucleotide polymorphism in promoter region with type 2 diabetes mellitus J. Cell. Biochem. 2018 119 5343 5349 10.1002/jcb.26667 29323730

48. Xu H. Ding Q. Jiang H.W. Genetic polymorphism of interleukin-1a (IL-1a), IL-1b, and IL-1 receptor antagonist (IL-1rn) and prostate cancer risk Asian Pac. J. Cancer Prev. 2014 15 8741 8747 10.7314/APJCP.2014.15.20.8741 25374200

49. Marucha P.T. Zeff R.A. Kreutzer D.L. Cytokine-induced IL-1 beta gene expression in the human polymorphonuclear leukocyte: Transcriptional and post-transcriptional regulation by tumor necrosis factor and IL-1 J. Immunol. 1991 147 2603 2608 1918980

50. Donnelly R.P. Fenton M.J. Kaufman J.D. Gerrard T.L. IL-1 expression in human monocytes is transcriptionally and posttranscriptionally regulated by IL-4 J. Immunol. 1991 146 3431 3436 2026872

51. Singh A.K. Aryal B. Zhang X. Fan Y. Price N.L. Suarez Y. Fernandez-Hernando C. Posttranscriptional regulation of lipid metabolism by non-coding RNAs and RNA binding proteins Semin Cell Dev. Biol. 2017 10.1016/j.semcdb.2017.11.026 29183708 PMC5975105

52. Sirenko O.I. Lofquist A.K. DeMaria C.T. Morris J.S. Brewer G. Haskill J.S. Adhesion-dependent regulation of an a+u-rich element-binding activity associated with AUF1 Mol. Cell. Biol. 1997 17 3898 3906 10.1128/MCB.17.7.3898 9199324 PMC232242

53. Bros M. Wiechmann N. Besche V. Art J. Pautz A. Grabbe S. Kleinert H. Reske-Kunz A.B. The rna binding protein tristetraprolin influences the activation state of murine dendritic cells Mol. Immunol. 2010 47 1161 1170 10.1016/j.molimm.2009.11.002 19945750

54. Kwak A. Lee Y. Kim H. Kim S. Intracellular interleukin (IL)-1 family cytokine processing enzyme Arch. Pharm. Res. 2016 39 1556 1564 10.1007/s12272-016-0855-0 27826753

55. Afonina I.S. Muller C. Martin S.J. Beyaert R. Proteolytic processing of interleukin-1 family cytokines: Variations on a common theme Immunity 2015 42 991 1004 10.1016/j.immuni.2015.06.003 26084020

56. Boatright K.M. Salvesen G.S. Mechanisms of caspase activation Curr. Opin. Cell Biol. 2003 15 725 731 10.1016/j.ceb.2003.10.009 14644197

57. Awad F. Assrawi E. Jumeau C. Georgin-Lavialle S. Cobret L. Duquesnoy P. Piterboth W. Thomas L. Stankovic-Stojanovic K. Louvrier C. Impact of human monocyte and macrophage polarization on nlr expression and NLRP3 inflammasome activation PLoS ONE 2017 12 e0175336 10.1371/journal.pone.0175336 28403163 PMC5389804

58. Haneklaus M. Gerlic M. Kurowska-Stolarska M. Rainey A.A. Pich D. McInnes I.B. Hammerschmidt W. O’Neill L.A. Masters S.L. Cutting edge: miR-223 and EBV miR-BART15 regulate the NLRP3 inflammasome and IL-1beta production J. Immunol. 2012 189 3795 3799 10.4049/jimmunol.1200312 22984081

59. Zhang Y. Liu C. Peng H. Zhang J. Feng Q. IL1 receptor antagonist gene IL1-RN variable number of tandem repeats polymorphism and cancer risk: A literature review and meta-analysis PLoS ONE 2012 7 e46017 10.1371/journal.pone.0046017 23049925 PMC3457944

60. Aziz F. The emerging role of miR-223 as novel potential diagnostic and therapeutic target for inflammatory disorders Cell. Immunol. 2016 303 1 6 10.1016/j.cellimm.2016.04.003 27129807

61. Juliana C. Fernandes-Alnemri T. Kang S. Farias A. Qin F. Alnemri E.S. Non-transcriptional priming and deubiquitination regulate nlrp3 inflammasome activation J. Biol. Chem. 2012 287 36617 36622 10.1074/jbc.M112.407130 22948162 PMC3476327

62. He Y. Zeng M.Y. Yang D. Motro B. Nunez G. NEK7 is an essential mediator of nlrp3 activation downstream of potassium efflux Nature 2016 530 354 357 10.1038/nature16959 26814970 PMC4810788

63. Kinoshita T. Imamura R. Kushiyama H. Suda T. NLRP3 mediates nf-kappab activation and cytokine induction in microbially induced and sterile inflammation PLoS ONE 2015 10 e0119179 10.1371/journal.pone.0119179 25761061 PMC4356585

64. Hernandez-Cuellar E. Tsuchiya K. Hara H. Fang R. Sakai S. Kawamura I. Akira S. Mitsuyama M. Cutting edge: Nitric oxide inhibits the NLRP3 inflammasome J. Immunol. 2012 189 5113 5117 10.4049/jimmunol.1202479 23100513

65. Vande Walle L. Van Opdenbosch N. Jacques P. Fossoul A. Verheugen E. Vogel P. Beyaert R. Elewaut D. Kanneganti T.D. van Loo G. Negative regulation of the NLRP3 inflammasome by A20 protects against arthritis Nature 2014 512 69 73 10.1038/nature13322 25043000 PMC4126806

66. Sokolowska M. Chen L.Y. Liu Y. Martinez-Anton A. Qi H.Y. Logun C. Alsaaty S. Park Y.H. Kastner D.L. Chae J.J. Prostaglandin E2 inhibits NLRP3 inflammasome activation through EP4 receptor and intracellular cyclic amp in human macrophages J. Immunol. 2015 194 5472 5487 10.4049/jimmunol.1401343 25917098 PMC4433768

67. Hua K.F. Chou J.C. Ka S.M. Tasi Y.L. Chen A. Wu S.H. Chiu H.W. Wong W.T. Wang Y.F. Tsai C.L. Cyclooxygenase-2 regulates NLRP3 inflammasome-derived IL-1beta production J. Cell. Physiol. 2015 230 863 874 10.1002/jcp.24815 25294243

68. Lorey M.B. Rossi K. Eklund K.K. Nyman T.A. Matikainen S. Global characterization of protein secretion from human macrophages following non-canonical caspase-4/5 inflammasome activation Mol. Cell. Proteom. 2017 16 S187 S199 10.1074/mcp.M116.064840 28196878 PMC5393394

69. Kayagaki N. Wong M.T. Stowe I.B. Ramani S.R. Gonzalez L.C. Akashi-Takamura S. Miyake K. Zhang J. Lee W.P. Muszynski A. Noncanonical inflammasome activation by intracellular LPS independent of TLR4 Science 2013 341 1246 1249 10.1126/science.1240248 23887873

70. Gao Y.L. Zhai J.H. Chai Y.F. Recent advances in the molecular mechanisms underlying pyroptosis in sepsis Mediat. Inflamm. 2018 2018 5823823 10.1155/2018/5823823 29706799 PMC5863298

71. Gaidt M.M. Ebert T.S. Chauhan D. Schmidt T. Schmid-Burgk J.L. Rapino F. Robertson A.A. Cooper M.A. Graf T. Hornung V. Human monocytes engage an alternative inflammasome pathway Immunity 2016 44 833 846 10.1016/j.immuni.2016.01.012 27037191

72. Tummers B. Green D.R. Caspase-8: Regulating life and death Immunol. Rev. 2017 277 76 89 10.1111/imr.12541 28462525 PMC5417704

73. Antonopoulos C. Russo H.M. El Sanadi C. Martin B.N. Li X. Kaiser W.J. Mocarski E.S. Dubyak G.R. Caspase-8 as an effector and regulator of NLRP3 inflammasome signaling J. Biol. Chem. 2015 290 20167 20184 10.1074/jbc.M115.652321 26100631 PMC4536427

74. Man S.M. Kanneganti T.D. Regulation of inflammasome activation Immunol. Rev. 2015 265 6 21 10.1111/imr.12296 25879280 PMC4400844

75. Bossaller L. Chiang P.I. Schmidt-Lauber C. Ganesan S. Kaiser W.J. Rathinam V.A. Mocarski E.S. Subramanian D. Green D.R. Silverman N. Cutting edge: FAS (CD95) mediates noncanonical IL-1beta and IL-18 maturation via caspase-8 in an RIP3-independent manner J. Immunol. 2012 189 5508 5512 10.4049/jimmunol.1202121 23144495 PMC3518757

76. Moriwaki K. Bertin J. Gough P.J. Chan F.K. A RIPK3-caspase 8 complex mediates atypical pro-IL-1beta processing J. Immunol. 2015 194 1938 1944 10.4049/jimmunol.1402167 25567679 PMC4324020

77. Mortimer L. Moreau F. MacDonald J.A. Chadee K. NLRP3 inflammasome inhibition is disrupted in a group of auto-inflammatory disease caps mutations Nat. Immunol. 2016 17 1176 1186 10.1038/ni.3538 27548431

78. Kitamura A. Sasaki Y. Abe T. Kano H. Yasutomo K. An inherited mutation in NLRC4 causes autoinflammation in human and mice J. Exp. Med. 2014 211 2385 2396 10.1084/jem.20141091 25385754 PMC4235634

79. Baroja-Mazo A. Martin-Sanchez F. Gomez A.I. Martinez C.M. Amores-Iniesta J. Compan V. Barbera-Cremades M. Yague J. Ruiz-Ortiz E. Anton J. The NLRP3 inflammasome is released as a particulate danger signal that amplifies the inflammatory response Nat. Immunol. 2014 15 738 748 10.1038/ni.2919 24952504

80. Sui J. Li H. Fang Y. Liu Y. Li M. Zhong B. Yang F. Zou Q. Wu Y. Nlrp1 gene polymorphism influences gene transcription and is a risk factor for rheumatoid arthritis in han Chinese Arthritis Rheum 2012 64 647 654 10.1002/art.33370 21976003

81. Dwivedi M. Laddha N.C. Mansuri M.S. Marfatia Y.S. Begum R. Association of NLRP1 genetic variants and mrna overexpression with generalized vitiligo and disease activity in a gujarat population Br. J. Dermatol. 2013 169 1114 1125 10.1111/bjd.12467 23773036

82. Alfakry H. Malle E. Koyani C.N. Pussinen P.J. Sorsa T. Neutrophil proteolytic activation cascades: A possible mechanistic link between chronic periodontitis and coronary heart disease Innate Immun. 2016 22 85 99 10.1177/1753425915617521 26608308

83. Xu H. Bin N.R. Sugita S. Diverse exocytic pathways for mast cell mediators Biochem. Soc. Trans. 2018 46 235 247 10.1042/BST20170450 29472369 PMC5986074

84. MacKenzie A. Wilson H.L. Kiss-Toth E. Dower S.K. North R.A. Surprenant A. Rapid secretion of interleukin-1beta by microvesicle shedding Immunity 2001 15 825 835 10.1016/S1074-7613(01)00229-1 11728343

85. Pizzirani C. Ferrari D. Chiozzi P. Adinolfi E. Sandona D. Savaglio E. Di Virgilio F. Stimulation of P2 receptors causes release of IL-1beta-loaded microvesicles from human dendritic cells Blood 2007 109 3856 3864 10.1182/blood-2005-06-031377 17192399

86. Le Feuvre R. Brough D. Rothwell N. Extracellular ATP and P2X7 receptors in neurodegeneration Eur. J. Pharmacol. 2002 447 261 269 10.1016/S0014-2999(02)01848-4 12151017

87. Stoeckle C. Sommandas V. Adamopoulou E. Belisle K. Schiekofer S. Melms A. Weber E. Driessen C. Boehm B.O. Tolosa E. Cathepsin g is differentially expressed in primary human antigen-presenting cells Cell. Immunol. 2009 255 41 45 10.1016/j.cellimm.2008.10.001 19036358

88. Trzybulska D. Olewicz-Gawlik A. Graniczna K. Kisiel K. Moskal M. Cieslak D. Sikora J. Hrycaj P. Quantitative analysis of elastase and cathepsin G mRNA levels in peripheral blood CD14(+) cells from patients with rheumatoid arthritis Cell. Immunol. 2014 292 40 44 10.1016/j.cellimm.2014.08.009 25248056

89. O’Neill L.A. The interleukin-1 receptor/toll-like receptor superfamily: 10 years of progress Immunol. Rev. 2008 226 10 18 10.1111/j.1600-065X.2008.00701.x 19161412

90. Boraschi D. Italiani P. Weil S. Martin M.U. The family of the interleukin-1 receptors Immunol. Rev. 2018 281 197 232 10.1111/imr.12606 29248002

91. Mcmahan C.J. Slack J.L. Mosley B. Cosman D. Lupton S.D. Brunton L.L. Grubin C.E. Wignall J.M. Jenkins N.A. Brannan C.I. A novel IL-1 receptor, cloned from B-cells by mammalian expression, is expressed in many cell-types EMBO J. 1991 10 2821 2832 1833184 10.1002/j.1460-2075.1991.tb07831.x PMC452992

92. Colotta F. Dower S.K. Sims J.E. Mantovani A. The type ii ‘decoy’ receptor: A novel regulatory pathway for interleukin 1 Immunol. Today 1994 15 562 566 10.1016/0167-5699(94)90217-8 7848516

93. Colotta F. Re F. Muzio M. Bertini R. Polentarutti N. Sironi M. Giri J.G. Dower S.K. Sims J.E. Mantovani A. Interleukin-1 type-II receptor—A decoy target for IL-1 that is regulated by IL-4 Science 1993 261 472 475 10.1126/science.8332913 8332913

94. Martin P. Palmer G. Vigne S. Lamacchia C. Rodriguez E. Talabot-Ayer D. Rose-John S. Chalaris A. Gabay C. Mouse neutrophils express the decoy type 2 interleukin-1 receptor (IL-1R2) constitutively and in acute inflammatory conditions J. Leukoc. Biol. 2013 94 791 802 10.1189/jlb.0113035 23817563

95. Shimizu K. Nakajima A. Sudo K. Liu Y. Mizoroki A. Ikarashi T. Horai R. Kakuta S. Watanabe T. Iwakura Y. IL-1 receptor type 2 suppresses collagen-induced arthritis by inhibiting IL-1 signal on macrophages J. Immunol. 2015 194 3156 3168 10.4049/jimmunol.1402155 25725107

96. Lingel A. Weiss T.M. Niebuhr M. Pan B. Appleton B.A. Wiesmann C. Bazan J.F. Fairbrother W.J. Structure of il-33 and its interaction with the ST2 and IL-1RACP receptors-insight into heterotrimeric IL-1 signaling complexes Structure 2009 17 1398 1410 10.1016/j.str.2009.08.009 19836339 PMC2766095

97. Vigers G.P. Anderson L.J. Caffes P. Brandhuber B.J. Crystal structure of the type-i interleukin-1 receptor complexed with interleukin-1beta Nature 1997 386 190 194 10.1038/386190a0 9062193

98. Schreuder H. Tardif C. Trump-Kallmeyer S. Soffientini A. Sarubbi E. Akeson A. Bowlin T. Yanofsky S. Barrett R.W. A new cytokine-receptor binding mode revealed by the crystal structure of the IL-1 receptor with an antagonist Nature 1997 386 194 200 10.1038/386194a0 9062194

99. Korherr C. Hofmeister R. Wesche H. Falk W. A critical role for interleukin-1 receptor accessory protein in interleukin-1 signaling Eur. J. Immunol. 1997 27 262 267 10.1002/eji.1830270139 9022028

100. Lang D. Knop J. Wesche H. Raffetseder U. Kurrle R. Boraschi D. Martin M.U. The type ii IL-1 receptor interacts with the IL-1 receptor accessory protein: A novel mechanism of regulation of IL-1 responsiveness J. Immunol. 1998 161 6871 6877 9862719

101. Greenfeder S.A. Nunes P. Kwee L. Labow M. Chizzonite R.A. Ju G. Molecular cloning and characterization of a second subunit of the interleukin 1 receptor complex J. Biol. Chem. 1995 270 13757 13765 10.1074/jbc.270.23.13757 7775431

102. Muzio M. Ni J. Feng P. Dixit V.M. IRAK (pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling Science 1997 278 1612 1615 10.1126/science.278.5343.1612 9374458

103. Wesche H. Henzel W.J. Shillinglaw W. Li S. Cao Z.D. MyD88: An adapter that recruits IRAK to the IL-1 receptor complex Immunity 1997 7 837 847 10.1016/S1074-7613(00)80402-1 9430229

104. Medzhitov R. Preston-Hurlburt P. Kopp E. Stadlen A. Chen C.Q. Ghosh S. Janeway C.A. MyD88 is an adaptor protein in the htoll/IL-1 receptor family signaling pathways Mol. Cell 1998 2 253 258 10.1016/S1097-2765(00)80136-7 9734363

105. Burns K. Martinon F. Esslinger C. Pahl H. Schneider P. Bodmer J.L. Di Marco F. French L. Tschopp J. MyD88, an adapter protein involved in interleukin-1 signaling J. Biol. Chem. 1998 273 12203 12209 10.1074/jbc.273.20.12203 9575168

106. Ferrao R. Wu H. Helical assembly in the death domain (DD) superfamily Curr. Opin. Struct. Biol. 2012 22 241 247 10.1016/j.sbi.2012.02.006 22429337 PMC3320699

107. Motshwene P.G. Moncrieffe M.C. Grossmann J.G. Kao C. Ayaluru M. Sandercock A.M. Robinson C.V. Latz E. Gay N.J. An oligomeric signaling platform formed by the toll-like receptor signal transducers MyD88 and IRAK-4 J. Biol. Chem. 2009 284 25404 25411 10.1074/jbc.M109.022392 19592493 PMC2757241

108. Dossang A.C.G. Motshwene P.G. Yang Y. Symmons M.F. Bryant C.E. Borman S. George J. Weber A.N.R. Gay N.J. The N-terminal loop of IRAK-4 death domain regulates ordered assembly of the myddosome signalling scaffold Sci. Rep. 2016 6 10.1038/srep37267 27876844 PMC5120336

109. Burns K. Clatworthy J. Martin L. Martinon F. Plumpton C. Maschera B. Lewis A. Ray K. Tschopp J. Volpe F. Tollip, a new component of the IL-1RI pathway, links irak to the IL-1 receptor Nat. Cell Biol. 2000 2 346 351 10.1038/35014038 10854325

110. Moynagh P.N. The roles of pellino e3 ubiquitin ligases in immunity Nat. Rev. Immunol. 2014 14 122 131 10.1038/nri3599 24445667

111. Li S. Strelow A. Fontana E.J. Wesche H. Irak-4: A novel member of the irak family with the properties of an irak-kinase Proc. Natl. Acad. Sci. USA 2002 99 5567 5572 10.1073/pnas.082100399 11960013 PMC122810

112. Kollewe C. Mackensen A.C. Neumann D. Knop J. Cao P. Li S.U. Wesche H. Martin M.U. Sequential autophosphorylation steps in the interleukin-1 receptor-associated kinase-1 regulate its availability as an adapter in interleukin-1 signaling J. Biol. Chem. 2004 279 5227 5236 10.1074/jbc.M309251200 14625308

113. Baud V. Liu Z.G. Bennett B. Suzuki N. Xia Y. Karin M. Signaling by proinflammatory cytokines: Oligomerization of TRAF2 and TRAF6 is sufficient for JNK and IKK activation and target gene induction via an amino-terminal effector domain Genes Dev. 1999 13 1297 1308 10.1101/gad.13.10.1297 10346818 PMC316725

114. Ordureau A. Smith H. Windheim M. Peggie M. Carrick E. Morrice N. Cohen P. The IRAK-catalysed activation of the E3 ligase function of pellino isoforms induces the Lys63-linked polyubiquitination of IRAK1 Biochem. J. 2008 409 43 52 10.1042/BJ20071365 17997719 PMC5791886

115. Smith H. Peggie M. Campbell D.G. Vandermoere F. Carrick E. Cohen P. Identification of the phosphorylation sites on the E3 ubiquitin ligase pellino that are critical for activation by IRAK1 and IRAK4 Proc. Natl. Acad. Sci. USA 2009 106 4584 4590 10.1073/pnas.0900774106 19264966 PMC2651833

116. Strickson S. Emmerich C.H. Goh E.T.H. Zhang J. Kelsall I.R. Macartney T. Hastie C.J. Knebel A. Peggie M. Marchesi F. Roles of the TRAF6 and pellino E3 ligases in MyD88 and RANKl signaling Proc. Natl. Acad. Sci. USA 2017 114 E3481 E3489 10.1073/pnas.1702367114 28404732 PMC5410814

117. Shim J.H. Xiao C.C. Paschal A.E. Bailey S.T. Rao P. Hayden M.S. Lee K.Y. Bussey C. Steckel M. Tanaka N. TAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivo Genes Dev. 2005 19 2668 2681 10.1101/gad.1360605 16260493 PMC1283960

118. Sato S. Sanjo H. Takeda K. Ninomiya-Tsuji J. Yamamoto M. Kawai T. Matsumoto K. Takeuchi O. Akira S. Essential function for the kinase TAK1 in innate and adaptive immune responses Nat. Immunol. 2005 6 1087 1095 10.1038/ni1255 16186825

119. Hirata Y. Takahashi M. Morishita T. Noguchi T. Matsuzawa A. Post-translational modifications of the TAK1-TAB complex Int. J. Mol. Sci. 2017 18 205 10.3390/ijms18010205 28106845 PMC5297835

120. Pauls E. Nanda S.K. Smith H. Toth R. Arthur J.S.C. Cohen P. Two phases of inflammatory mediator production defined by the study of IRAK2 and IRAK1 knock-in mice J. Immunol. 2013 191 2717 2730 10.4049/jimmunol.1203268 23918981 PMC3849919

121. Vigers G.P. Caffes P. Evans R.J. Thompson R.C. Eisenberg S.P. Brandhuber B.J. X-ray structure of interleukin-1 receptor antagonist at 2.0-A resolution J. Biol. Chem. 1994 269 12874 12879 8175703

122. Arend W.P. Guthridge C.J. Biological role of interleukin 1 receptor antagonist isoforms Ann. Rheum. Dis. 2000 59 Suppl. 1 i60 i64 10.1136/ard.59.suppl_1.i60 11053091 PMC1766634

123. Bellehumeur C. Blanchet J. Fontaine J.Y. Bourcier N. Akoum A. Interleukin 1 regulates its own receptors in human endometrial cells via distinct mechanisms Hum. Reprod. 2009 24 2193 2204 10.1093/humrep/dep192 19477877

124. Dinarello C.A. van der Meer J.W. Treating inflammation by blocking interleukin-1 in humans Semin. Immunol. 2013 25 469 484 10.1016/j.smim.2013.10.008 24275598 PMC3953875

125. Meyer N.J. Ferguson J.F. Feng R. Wang F. Patel P.N. Li M. Xue C. Qu L. Liu Y. Boyd J.H. A functional synonymous coding variant in the IL1rn gene is associated with survival in septic shock Am. J. Respir. Crit. Care Med. 2014 190 656 664 10.1164/rccm.201403-0586OC 25089931 PMC4214110

126. Kollewe C. Neumann D. Martin M.U. The first two N-terminal immunoglobulin-like domains of soluble human IL-1 receptor type II are sufficient to bind and neutralize IL-1beta FEBS Lett. 2000 487 189 193 10.1016/S0014-5793(00)02345-0 11150507

127. Neumann D. Kollewe C. Martin M.U. Boraschi D. The membrane form of the type ii IL-1 receptor accounts for inhibitory function J. Immunol. 2000 165 3350 3357 10.4049/jimmunol.165.6.3350 10975853

128. Reddy P. Slack J.L. Davis R. Cerretti D.P. Kozlosky C.J. Blanton R.A. Shows D. Peschon J.J. Black R.A. Functional analysis of the domain structure of tumor necrosis factor-alpha converting enzyme J. Biol. Chem. 2000 275 14608 14614 10.1074/jbc.275.19.14608 10799547

129. Lorenzen I. Lokau J. Dusterhoft S. Trad A. Garbers C. Scheller J. Rose-John S. Grotzinger J. The membrane-proximal domain of A Disintegrin and Metalloprotease 17 (ADAM17) is responsible for recognition of the interleukin-6 receptor and interleukin-1 receptor II FEBS Lett. 2012 586 1093 1100 10.1016/j.febslet.2012.03.012 22575642

130. Cui X.L. Rouhani F.N. Hawari F. Levine S.J. Shedding of the type II IL-1 decoy receptor requires a multifunctional aminopeptidase, aminopeptidase regulator of tnf receptor type 1 shedding J. Immunol. 2003 171 6814 6819 10.4049/jimmunol.171.12.6814 14662887

131. Kuhn P.H. Marjaux E. Imhof A. De Strooper B. Haass C. Lichtenthaler S.F. Regulated intramembrane proteolysis of the interleukin-1 receptor II by alpha-, beta-, and gamma-secretase J. Biol. Chem. 2007 282 11982 11995 10.1074/jbc.M700356200 17307738

132. Liu C.L. Hart R.P. Liu X.J. Clevenger W. Maki R.A. DeSouza E.B. Cloning and characterization of an alternatively processed human type ii interleukin-1 receptor mrna J. Biol. Chem. 1996 271 20965 20972 10.1074/jbc.271.34.20965 8702856

133. Jensen L.E. Muzio M. Mantovani A. Whitehead A.S. IL-1 signaling cascade in liver cells and the involvement of a soluble form of the IL-1 receptor accessory protein J. Immunol. 2000 164 5277 5286 10.4049/jimmunol.164.10.5277 10799889

134. Peters V.A. Joesting J.J. Freund G.G. IL-1 receptor 2 (IL-1R2) and its role in immune regulation Brain Behav. Immun. 2013 32 1 8 10.1016/j.bbi.2012.11.006 23195532 PMC3610842

135. Vambutas A. DeVoti J. Goldofsky E. Gordon M. Lesser M. Bonagura V. Alternate splicing of interleukin-1 receptor type ii (IL1R2) in vitro correlates with clinical glucocorticoid responsiveness in patients with aied PLoS ONE 2009 4 10.1371/journal.pone.0005293 19401759 PMC2670509

136. Mora-Buch R. Dotti I. Planell N. Calderon-Gomez E. Jung P. Masamunt M.C. Llach J. Ricart E. Batlle E. Panes J. Epithelial IL-1R2 acts as a homeostatic regulator during remission of ulcerative colitis Mucosal Immunol. 2016 9 950 959 10.1038/mi.2015.108 26530134 PMC4917674

137. Mochizuki D.Y. Eisenman J.R. Conlon P.J. Larsen A.D. Tushinski R.J. Interleukin 1 regulates hematopoietic activity, a role previously ascribed to hemopoietin 1 Proc. Natl. Acad. Sci. USA 1987 84 5267 5271 10.1073/pnas.84.15.5267 2885846 PMC298836

138. Neta R. Douches S. Oppenheim J.J. Interleukin 1 is a radioprotector J. Immunol. 1986 136 2483 2485 3512714

139. Yoshimura A. Mori H. Ohishi M. Aki D. Hanada T. Negative regulation of cytokine signaling influences inflammation Curr. Opin. Immunol. 2003 15 704 708 10.1016/j.coi.2003.09.004 14630206

140. Walsh M.C. Kim G.K. Maurizio P.L. Molnar E.E. Choi Y. TRAF6 autoubiquitination-independent activation of the NFkappab and MAPK pathways in response to IL-1 and RANKL PLoS ONE 2008 3 e4064 10.1371/journal.pone.0004064 19112497 PMC2603309

141. Brinson C.W. Lu Z. Li Y. Lopes-Virella M.F. Huang Y. Lipopolysaccharide and IL-1beta coordinate a synergy on cytokine production by upregulating MyD88 expression in human gingival fibroblasts Mol. Immunol. 2016 79 47 54 10.1016/j.molimm.2016.09.020 27697591 PMC5138110

142. Koide S.L. Inaba K. Steinman R.M. Interleukin 1 enhances T-dependent immune responses by amplifying the function of dendritic cells J. Exp. Med. 1987 165 515 530 10.1084/jem.165.2.515 2950198 PMC2188514

143. Heufler C. Koch F. Schuler G. Granulocyte/macrophage colony-stimulating factor and interleukin 1 mediate the maturation of murine epidermal langerhans cells into potent immunostimulatory dendritic cells J. Exp. Med. 1988 167 700 705 10.1084/jem.167.2.700 3279156 PMC2188828

144. Schenk M. Fabri M. Krutzik S.R. Lee D.J. Vu D.M. Sieling P.A. Montoya D. Liu P.T. Modlin R.L. Interleukin-1beta triggers the differentiation of macrophages with enhanced capacity to present mycobacterial antigen to t cells Immunology 2014 141 174 180 10.1111/imm.12167 24032597 PMC3904238

145. Lipsky P.E. Thompson P.A. Rosenwasser L.J. Dinarello C.A. The role of interleukin 1 in human b cell activation: Inhibition of B cell proliferation and the generation of immunoglobulin-secreting cells by an antibody against human leukocytic pyrogen J. Immunol. 1983 130 2708 2714 6222114

146. Ben Aribia M.H. Leroy E. Lantz O. Metivier D. Autran B. Charpentier B. Hercend T. Senik A. rIL 2-induced proliferation of human circulating nk cells and t lymphocytes: Synergistic effects of IL 1 and IL 2 J. Immunol. 1987 139 443 451 3110271

147. Ben-Sasson S.Z. Wang K. Cohen J. Paul W.E. IL-1beta strikingly enhances antigen-driven CD4 and CD8 T-cell responses Cold Spring Harb. Symp. Quant. Biol. 2013 78 117 124 10.1101/sqb.2013.78.021246 24092469

148. Hutton H.L. Ooi J.D. Holdsworth S.R. Kitching A.R. The NLRP3 inflammasome in kidney disease and autoimmunity Nephrology (Carlton) 2016 21 736 744 10.1111/nep.12785 27011059

149. McArthur J.G. Raulet D.H. CD28-induced costimulation of T helper type 2 cells mediated by induction of responsiveness to interleukin 4 J. Exp. Med. 1993 178 1645 1653 10.1084/jem.178.5.1645 8228811 PMC2191256

150. Acosta-Rodriguez E.V. Napolitani G. Lanzavecchia A. Sallusto F. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human t helper cells Nat. Immunol. 2007 8 942 949 10.1038/ni1496 17676045

151. Sutton C. Brereton C. Keogh B. Mills K.H. Lavelle E.C. A crucial role for interleukin (IL)-1 in the induction of IL-17-producing t cells that mediate autoimmune encephalomyelitis J. Exp. Med. 2006 203 1685 1691 10.1084/jem.20060285 16818675 PMC2118338

152. Ikeda S. Saijo S. Murayama M.A. Shimizu K. Akitsu A. Iwakura Y. Excess IL-1 signaling enhances the development of Th17 cells by downregulating TGF-beta-induced Foxp3 expression J. Immunol. 2014 192 1449 1458 10.4049/jimmunol.1300387 24431229

153. Mailer R.K. Joly A.L. Liu S. Elias S. Tegner J. Andersson J. IL-1beta promotes Th17 differentiation by inducing alternative splicing of FOXP3 Sci. Rep. 2015 5 14674 10.1038/srep14674 26441347 PMC4593960

154. Ilarregui J.M. van Beelen A.J. Fehres C.M. Bruijns S.C. Garcia-Vallejo J.J. van Kooyk Y. New roles for CD14 and IL-beta linking inflammatory dendritic cells to IL-17 production in memory CD4(+) t cells Immunol. Cell. Biol. 2016 94 907 916 10.1038/icb.2016.66 27550748

155. Zielinski C.E. Mele F. Aschenbrenner D. Jarrossay D. Ronchi F. Gattorno M. Monticelli S. Lanzavecchia A. Sallusto F. Pathogen-induced human Th17 cells produce ifn-gamma or IL-10 and are regulated by IL-1beta Nature 2012 484 514 518 10.1038/nature10957 22466287

156. Sutton C.E. Lalor S.J. Sweeney C.M. Brereton C.F. Lavelle E.C. Mills K.H. Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta t cells, amplifying Th17 responses and autoimmunity Immunity 2009 31 331 341 10.1016/j.immuni.2009.08.001 19682929

157. Kuldo J.M. Ogawara K.I. Werner N. Asgeirsdottir S.A. Kamps J.A. Kok R.J. Molema G. Molecular pathways of endothelial cell activation for (targeted) pharmacological intervention of chronic inflammatory diseases Curr. Vasc. Pharmacol. 2005 3 11 39 10.2174/1570161052773898 15638780

158. Miller L.S. O’Connell R.M. Gutierrez M.A. Pietras E.M. Shahangian A. Gross C.E. Thirumala A. Cheung A.L. Cheng G. Modlin R.L. MyD88 mediates neutrophil recruitment initiated by IL-1R but not TLR2 activation in immunity against staphylococcus aureus Immunity 2006 24 79 91 10.1016/j.immuni.2005.11.011 16413925

159. Abbate A. Canada J.M. Van Tassell B.W. Wise C.M. Dinarello C.A. Interleukin-1 blockade in rheumatoid arthritis and heart failure: A missed opportunity? Int. J. Cardiol. 2014 171 e125 e126 10.1016/j.ijcard.2013.12.078 24418290

160. Murray K.N. Parry-Jones A.R. Allan S.M. Interleukin-1 and acute brain injury Front. Cell. Neurosci. 2015 9 18 10.3389/fncel.2015.00018 25705177 PMC4319479

161. Tan C.C. Zhang J.G. Tan M.S. Chen H. Meng D.W. Jiang T. Meng X.F. Li Y. Sun Z. Li M.M. NLRP1 inflammasome is activated in patients with medial temporal lobe epilepsy and contributes to neuronal pyroptosis in amygdala kindling-induced rat model J. Neuroinflamm. 2015 12 18 10.1186/s12974-014-0233-0 25626361 PMC4314732

162. Fann D.Y. Lim Y.A. Cheng Y.L. Lok K.Z. Chunduri P. Baik S.H. Drummond G.R. Dheen S.T. Sobey C.G. Jo D.G. Evidence that NF-kappab and MAPK signaling promotes nlrp inflammasome activation in neurons following ischemic stroke Mol. Neurobiol. 2018 55 1082 1096 10.1007/s12035-017-0394-9 28092085

163. Tan M.S. Yu J.T. Jiang T. Zhu X.C. Tan L. The nlrp3 inflammasome in Alzheimer’s disease Mol. Neurobiol. 2013 48 875 882 10.1007/s12035-013-8475-x 23686772

164. Mamik M.K. Power C. Inflammasomes in neurological diseases: Emerging pathogenic and therapeutic concepts Brain J. Neurol. 2017 140 2273 2285 10.1093/brain/awx133 29050380

165. Dumusc A. So A. Interleukin-1 as a therapeutic target in gout Curr. Opin. Rheumatol. 2015 27 156 163 10.1097/BOR.0000000000000143 25633244

166. Pilli D. Zou A. Tea F. Dale R.C. Brilot F. Expanding role of t cells in human autoimmune diseases of the central nervous system Front. Immunol. 2017 8 652 10.3389/fimmu.2017.00652 28638382 PMC5461350

167. Striz I. Cytokines of the IL-1 family: Recognized targets in chronic inflammation underrated in organ transplantations Clin. Sci. (Lond.) 2017 131 2241 2256 10.1042/CS20170098 28798075

168. Maedler K. Sergeev P. Ris F. Oberholzer J. Joller-Jemelka H.I. Spinas G.A. Kaiser N. Halban P.A. Donath M.Y. Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets J. Clin. Investig. 2002 110 851 860 10.1172/JCI200215318 12235117 PMC151125

169. Masters S.L. Dunne A. Subramanian S.L. Hull R.L. Tannahill G.M. Sharp F.A. Becker C. Franchi L. Yoshihara E. Chen Z. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1beta in type 2 diabetes Nat. Immunol. 2010 11 897 904 10.1038/ni.1935 20835230 PMC3103663

170. Westwell-Roper C.Y. Ehses J.A. Verchere C.B. Resident macrophages mediate islet amyloid polypeptide-induced islet IL-1beta production and beta-cell dysfunction Diabetes 2014 63 1698 1711 10.2337/db13-0863 24222351

171. Boni-Schnetzler M. Donath M.Y. How biologics targeting the IL-1 system are being considered for the treatment of type 2 diabetes Br. J. Clin. Pharmacol. 2013 76 263 268 10.1111/j.1365-2125.2012.04297.x 22506644 PMC3731600

172. Huang Y. Chen R. Zhou J. E2f1 and nf-kappab: Key mediators of inflammation-associated cancers and potential therapeutic targets Curr. Cancer Drug Targets 2016 16 765 772 10.2174/1568009616666160216130755 26881929

173. Kim E.K. Choi E.J. Compromised mapk signaling in human diseases: An update Arch. Toxicol. 2015 89 867 882 10.1007/s00204-015-1472-2 25690731

174. Qu X. Tang Y. Hua S. Immunological approaches towards cancer and inflammation: A cross talk Front. Immunol. 2018 9 563 10.3389/fimmu.2018.00563 29662489 PMC5890100

175. Liegel J. Avigan D. Rosenblatt J. Cellular immunotherapy as a therapeutic approach in multiple myeloma Expert Rev. Hematol. 2018 11 525 536 10.1080/17474086.2018.1483718 29856648

176. Kyle R.A. Remstein E.D. Therneau T.M. Dispenzieri A. Kurtin P.J. Hodnefield J.M. Larson D.R. Plevak M.F. Jelinek D.F. Fonseca R. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma N. Engl. J. Med. 2007 356 2582 2590 10.1056/NEJMoa070389 17582068

177. Costes V. Portier M. Lu Z.Y. Rossi J.F. Bataille R. Klein B. Interleukin-1 in multiple myeloma: Producer cells and their role in the control of IL-6 production Br. J. Haematol. 1998 103 1152 1160 10.1046/j.1365-2141.1998.01101.x 9886334

178. Lust J.A. Lacy M.Q. Zeldenrust S.R. Witzig T.E. Moon-Tasson L.L. Dinarello C.A. Donovan K.A. Reduction in C-reactive protein indicates successful targeting of the IL-1/IL-6 axis resulting in improved survival in early stage multiple myeloma Am. J. Hematol. 2016 91 571 574 10.1002/ajh.24352 26945843

179. Nakamura S. Nakata K. Kashimoto S. Yoshida H. Yamada M. Antitumor effect of recombinant human interleukin 1 alpha against murine syngeneic tumors Jpn. J. Cancer Res. 1986 77 767 773 3093425

180. North R.J. Neubauer R.H. Huang J.J. Newton R.C. Loveless S.E. Interleukin 1-induced, T cell-mediated regression of immunogenic murine tumors. Requirement for an adequate level of already acquired host concomitant immunity J. Exp. Med. 1988 168 2031 2043 10.1084/jem.168.6.2031 3143799 PMC2189148

181. Allen I.C. TeKippe E.M. Woodford R.M. Uronis J.M. Holl E.K. Rogers A.B. Herfarth H.H. Jobin C. Ting J.P. The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer J. Exp. Med. 2010 207 1045 1056 10.1084/jem.20100050 20385749 PMC2867287

182. Haabeth O.A. Lorvik K.B. Hammarstrom C. Donaldson I.M. Haraldsen G. Bogen B. Corthay A. Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer Nat. Commun 2011 2 240 10.1038/ncomms1239 21407206 PMC3072106

183. Haabeth O.A. Lorvik K.B. Yagita H. Bogen B. Corthay A. Interleukin-1 is required for cancer eradication mediated by tumor-specific Th1 cells Oncoimmunology 2016 5 e1039763 10.1080/2162402X.2015.1039763 26942052 PMC4760324

184. Veltri S. Smith J.W. 2nd Interleukin 1 trials in cancer patients: A review of the toxicity, antitumor and hematopoietic effects Stem Cells 1996 14 164 176 10.1002/stem.140164 8991536

185. Mullerad J. Cohen S. Benharroch D. Apte R.N. Local delivery of IL-1 alpha polymeric microspheres for the immunotherapy of an experimental fibrosarcoma Cancer Investig. 2003 21 720 728 10.1081/CNV-120023770 14628430

186. Mullerad J. Cohen S. Voronov E. Apte R.N. Macrophage activation for the production of immunostimulatory cytokines by delivering interleukin 1 via biodegradable microspheres Cytokine 2000 12 1683 1690 10.1006/cyto.2000.0775 11052820

187. Hellstrom K.E. Dai M. Hellstrom I. Curing tumor-bearing mice by shifting a Th2 to a Th1 anti-tumor response Hum. Antibodies 2017 25 147 153 10.3233/HAB-160309 28085017

188. Llosa N.J. Geis A.L. Thiele Orberg E. Housseau F. Interleukin-17 and type 17 helper T cells in cancer management and research Immunotargets Ther. 2014 3 39 54 27471699 10.2147/ITT.S56529 PMC4918233

189. Mansilla S. Llovera L. Portugal J. Chemotherapeutic targeting of cell death pathways Anticancer Agents Med. Chem. 2012 12 226 238 10.2174/187152012800228805 22263795

190. Iyer S.S. Pulskens W.P. Sadler J.J. Butter L.M. Teske G.J. Ulland T.K. Eisenbarth S.C. Florquin S. Flavell R.A. Leemans J.C. Necrotic cells trigger a sterile inflammatory response through the nlrp3 inflammasome Proc. Natl. Acad. Sci. USA 2009 106 20388 20393 10.1073/pnas.0908698106 19918053 PMC2787135

191. Ghiringhelli F. Apetoh L. Tesniere A. Aymeric L. Ma Y. Ortiz C. Vermaelen K. Panaretakis T. Mignot G. Ullrich E. Activation of the nlrp3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors Nat. Med. 2009 15 1170 1178 10.1038/nm.2028 19767732

192. Mattarollo S.R. Loi S. Duret H. Ma Y. Zitvogel L. Smyth M.J. Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors Cancer Res. 2011 71 4809 4820 10.1158/0008-5472.CAN-11-0753 21646474

193. Mantovani A. Barajon I. Garlanda C. IL-1 and IL-1 regulatory pathways in cancer progression and therapy Immunol. Rev. 2018 281 57 61 10.1111/imr.12614 29247996 PMC5922413

194. Steel J.L. Terhorst L. Collins K.P. Geller D.A. Vodovotz Y. Kim J. Krane A. Antoni M. Marsh J.W. Burke L.E. Prospective analyses of cytokine mediation of sleep and survival in the context of advanced cancer Psychosom. Med. 2018 80 483 491 10.1097/PSY.0000000000000579 29621045 PMC5976532

195. Apte R.N. Krelin Y. Song X. Dotan S. Recih E. Elkabets M. Carmi Y. Dvorkin T. White R.M. Gayvoronsky L. Effects of micro-environment- and malignant cell-derived interleukin-1 in carcinogenesis, tumour invasiveness and tumour-host interactions Eur. J. Cancer 2006 42 751 759 10.1016/j.ejca.2006.01.010 16530403

196. Apte R.N. Dotan S. Elkabets M. White M.R. Reich E. Carmi Y. Song X. Dvozkin T. Krelin Y. Voronov E. The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions Cancer Metastasis Rev. 2006 25 387 408 10.1007/s10555-006-9004-4 17043764

197. Maker A.V. Katabi N. Qin L.X. Klimstra D.S. Schattner M. Brennan M.F. Jarnagin W.R. Allen P.J. Cyst fluid interleukin-1beta (IL1beta) levels predict the risk of carcinoma in intraductal papillary mucinous neoplasms of the pancreas Clin. Cancer Res. 2011 17 1502 1508 10.1158/1078-0432.CCR-10-1561 21266527 PMC3065716

198. Apte R.N. Voronov E. Is interleukin-1 a good or bad ‘guy’ in tumor immunobiology and immunotherapy? Immunol. Rev. 2008 222 222 241 10.1111/j.1600-065X.2008.00615.x 18364005

199. Li N. Grivennikov S.I. Karin M. The unholy trinity: Inflammation, cytokines, and stat3 shape the cancer microenvironment Cancer Cell 2011 19 429 431 10.1016/j.ccr.2011.03.018 21481782 PMC3111086

200. Nickoloff B.J. Ben-Neriah Y. Pikarsky E. Inflammation and cancer: Is the link as simple as we think? J. Investig. Dermatol. 2005 124 x xiv 10.1111/j.0022-202X.2005.23724.x 15955081

201. Sherman M. Risk of hepatocellular carcinoma in hepatitis b and prevention through treatment Clevel. Clin. J. Med. 2009 76 Suppl. 3 S6 S9 10.3949/ccjm.76.s3.02 19465708

202. Yi G. Liang M. Li M. Fang X. Liu J. Lai Y. Chen J. Yao W. Feng X. Hu L. A large lung gene expression study identifying IL1b as a novel player in airway inflammation in copd airway epithelial cells Inflamm. Res. 2018 67 539 551 10.1007/s00011-018-1145-8 29616282

203. Del Campo J.A. Gallego P. Grande L. Role of inflammatory response in liver diseases: Therapeutic strategies World J. Hepatol. 2018 10 1 7 10.4254/wjh.v10.i1.1 29399273 PMC5787673

204. Hong J.B. Zuo W. Wang A.J. Lu N.H. Helicobacter pylori infection synergistic with IL-1beta gene polymorphisms potentially contributes to the carcinogenesis of gastric cancer Int. J. Med. Sci. 2016 13 298 303 10.7150/ijms.14239 27076787 PMC4829543

205. El-Omar E.M. Carrington M. Chow W.H. McColl K.E. Bream J.H. Young H.A. Herrera J. Lissowska J. Yuan C.C. Rothman N. Interleukin-1 polymorphisms associated with increased risk of gastric cancer Nature 2000 404 398 402 10.1038/35006081 10746728

206. Shigematsu Y. Niwa T. Rehnberg E. Toyoda T. Yoshida S. Mori A. Wakabayashi M. Iwakura Y. Ichinose M. Kim Y.J. Interleukin-1beta induced by helicobacter pylori infection enhances mouse gastric carcinogenesis Cancer Lett. 2013 340 141 147 10.1016/j.canlet.2013.07.034 23920123

207. Huang F.Y. Chan A.O. Rashid A. Wong D.K. Seto W.K. Cho C.H. Lai C.L. Yuen M.F. Interleukin-1beta increases the risk of gastric cancer through induction of aberrant DNA methylation in a mouse model Oncol. Lett. 2016 11 2919 2924 10.3892/ol.2016.4296 27073577 PMC4812546

208. Sandri B.J. Kaplan A. Hodgson S.W. Peterson M. Avdulov S. Higgins L. Markowski T. Yang P. Limper A.H. Griffin T.J. Multi-omic molecular profiling of lung cancer in chronic obstructive pulmonary disease Eur. Respir. J. 2018 52 10.1183/13993003.02665-2017 29794131 PMC6618293

209. Krelin Y. Voronov E. Dotan S. Elkabets M. Reich E. Fogel M. Huszar M. Iwakura Y. Segal S. Dinarello C.A. Interleukin-1beta-driven inflammation promotes the development and invasiveness of chemical carcinogen-induced tumors Cancer Res. 2007 67 1062 1071 10.1158/0008-5472.CAN-06-2956 17283139

210. Mukaida N. Nakamoto Y. Emergence of immunotherapy as a novel way to treat hepatocellular carcinoma World J. Gastroenterol. 2018 24 1839 1858 10.3748/wjg.v24.i17.1839 29740200 PMC5937202

211. Kanterman J. Sade-Feldman M. Baniyash M. New insights into chronic inflammation-induced immunosuppression Semin. Cancer Biol. 2012 22 307 318 10.1016/j.semcancer.2012.02.008 22387003

212. Galdiero M.R. Bonavita E. Barajon I. Garlanda C. Mantovani A. Jaillon S. Tumor associated macrophages and neutrophils in cancer Immunobiology 2013 218 1402 1410 10.1016/j.imbio.2013.06.003 23891329

213. Mishalian I. Granot Z. Fridlender Z.G. The diversity of circulating neutrophils in cancer Immunobiology 2017 222 82 88 10.1016/j.imbio.2016.02.001 26874580

214. Belgiovine C. D’Incalci M. Allavena P. Frapolli R. Tumor-associated macrophages and anti-tumor therapies: Complex links Cell. Mol. Life Sci. 2016 73 2411 2424 10.1007/s00018-016-2166-5 26956893 PMC11108407

215. Biswas S.K. Allavena P. Mantovani A. Tumor-associated macrophages: Functional diversity, clinical significance, and open questions Semin. Immunopathol. 2013 35 585 600 10.1007/s00281-013-0367-7 23657835

216. Noy R. Pollard J.W. Tumor-associated macrophages: From mechanisms to therapy Immunity 2014 41 49 61 10.1016/j.immuni.2014.06.010 25035953 PMC4137410

217. Parker K.H. Beury D.W. Ostrand-Rosenberg S. Myeloid-derived suppressor cells: Critical cells driving immune suppression in the tumor microenvironment Adv. Cancer Res. 2015 128 95 139 26216631 10.1016/bs.acr.2015.04.002 PMC4662416

218. Kumar V. Patel S. Tcyganov E. Gabrilovich D.I. The nature of myeloid-derived suppressor cells in the tumor microenvironment Trends Immunol. 2016 37 208 220 10.1016/j.it.2016.01.004 26858199 PMC4775398

219. Baniyash M. Myeloid-derived suppressor cells as intruders and targets: Clinical implications in cancer therapy Cancer Immunol. Immunother. 2016 65 857 867 10.1007/s00262-016-1849-y 27225641 PMC11028840

220. De Sanctis F. Solito S. Ugel S. Molon B. Bronte V. Marigo I. Mdscs in cancer: Conceiving new prognostic and therapeutic targets Biochim. Biophys. Acta 2016 1865 35 48 10.1016/j.bbcan.2015.08.001 26255541

221. Keskinov A.A. Shurin M.R. Myeloid regulatory cells in tumor spreading and metastasis Immunobiology 2015 220 236 242 10.1016/j.imbio.2014.07.017 25178934

222. Voronov E. Apte R.N. Targeting the tumor microenvironment by intervention in interleukin-1 biology Curr. Pharm. Des. 2017 23 4893 4905 28606052 10.2174/1381612823666170613080919

223. Nishikawa H. [Regulatory T cells in cancer immunotherapy] Rinsho Ketsueki 2014 55 2183 2189 10.1016/j.coi.2013.12.005 25297785

224. Plitas G. Rudensky A.Y. Regulatory t cells: Differentiation and function Cancer Immunol. Res. 2016 4 721 725 10.1158/2326-6066.CIR-16-0193 27590281 PMC5026325

225. Han Y. Zhang Y. Jia T. Sun Y. Molecular mechanism underlying the tumor-promoting functions of carcinoma-associated fibroblasts Tumour. Biol. 2015 36 1385 1394 10.1007/s13277-015-3230-8 25680413

226. Chen L. Huang C.F. Li Y.C. Deng W.W. Mao L. Wu L. Zhang W.F. Zhang L. Sun Z.J. Blockage of the NLRP3 inflammasome by MCC950 improves anti-tumor immune responses in head and neck squamous cell carcinoma Cell. Mol. Life Sci. 2018 75 2045 2058 10.1007/s00018-017-2720-9 29184980 PMC11105265

227. Gabrilovich D.I. Ostrand-Rosenberg S. Bronte V. Coordinated regulation of myeloid cells by tumours Nat. Rev. Immunol. 2012 12 253 268 10.1038/nri3175 22437938 PMC3587148

228. Tanchot C. Terme M. Pere H. Tran T. Benhamouda N. Strioga M. Banissi C. Galluzzi L. Kroemer G. Tartour E. Tumor-infiltrating regulatory t cells: Phenotype, role, mechanism of expansion in situ and clinical significance Cancer Microenviron. 2013 6 147 157 10.1007/s12307-012-0122-y 23104434 PMC3717062

229. Jacobs J.F. Nierkens S. Figdor C.G. de Vries I.J. Adema G.J. Regulatory t cells in melanoma: The final hurdle towards effective immunotherapy? Lancet Oncol. 2012 13 e32 e42 10.1016/S1470-2045(11)70155-3 22225723

230. Minnema-Luiting J. Vroman H. Aerts J. Cornelissen R. Heterogeneity in immune cell content in malignant pleural mesothelioma Int. J. Mol. Sci. 2018 19 1041 10.3390/ijms19041041 29601534 PMC5979422

231. Mantovani A. Sozzani S. Locati M. Allavena P. Sica A. Macrophage polarization: Tumor-associated macrophages as a paradigm for polarized m2 mononuclear phagocytes Trends Immunol. 2002 23 549 555 10.1016/S1471-4906(02)02302-5 12401408

232. Guo B. Fu S. Zhang J. Liu B. Li Z. Targeting inflammasome/IL-1 pathways for cancer immunotherapy Sci. Rep. 2016 6 36107 10.1038/srep36107 27786298 PMC5082376

233. Lim S.Y. Yuzhalin A.E. Gordon-Weeks A.N. Muschel R.J. Targeting the CCL2-CCR2 signaling axis in cancer metastasis Oncotarget 2016 7 28697 28710 10.18632/oncotarget.7376 26885690 PMC5053756

234. Ostrand-Rosenberg S. Sinha P. Myeloid-derived suppressor cells: Linking inflammation and cancer J. Immunol. 2009 182 4499 4506 10.4049/jimmunol.0802740 19342621 PMC2810498

235. Liu Y. Wei G. Cheng W.A. Dong Z. Sun H. Lee V.Y. Cha S.C. Smith D.L. Kwak L.W. Qin H. Targeting myeloid-derived suppressor cells for cancer immunotherapy Cancer Immunol. Immunother. 2018 1036 105 128 10.1007/s00262-018-2175-3 29855694 PMC11028324

236. Tu S. Bhagat G. Cui G. Takaishi S. Kurt-Jones E.A. Rickman B. Betz K.S. Penz-Oesterreicher M. Bjorkdahl O. Fox J.G. Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice Cancer Cell 2008 14 408 419 10.1016/j.ccr.2008.10.011 18977329 PMC2586894

237. Ostrand-Rosenberg S. Myeloid-derived suppressor cells: More mechanisms for inhibiting antitumor immunity Cancer Immunol. Immunother. 2010 59 1593 1600 10.1007/s00262-010-0855-8 20414655 PMC3706261

238. Peranzoni E. Zilio S. Marigo I. Dolcetti L. Zanovello P. Mandruzzato S. Bronte V. Myeloid-derived suppressor cell heterogeneity and subset definition Curr. Opin. Immunol. 2010 22 238 244 10.1016/j.coi.2010.01.021 20171075

239. Poschke I. Mougiakakos D. Hansson J. Masucci G.V. Kiessling R. Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are stat3hi and overexpress CD80, CD83, and DC-sign Cancer Res. 2010 70 4335 4345 10.1158/0008-5472.CAN-09-3767 20484028

240. Condamine T. Gabrilovich D.I. Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function Trends Immunol. 2011 32 19 25 10.1016/j.it.2010.10.002 21067974 PMC3053028

241. Meyer C. Sevko A. Ramacher M. Bazhin A.V. Falk C.S. Osen W. Borrello I. Kato M. Schadendorf D. Baniyash M. Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model Proc. Natl. Acad. Sci. USA 2011 108 17111 17116 10.1073/pnas.1108121108 21969559 PMC3193202

242. Filipazzi P. Huber V. Rivoltini L. Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients Cancer Immunol. Immunother. 2012 61 255 263 10.1007/s00262-011-1161-9 22120756 PMC11029611

243. Solito S. Marigo I. Pinton L. Damuzzo V. Mandruzzato S. Bronte V. Myeloid-derived suppressor cell heterogeneity in human cancers Ann. N. Y. Acad. Sci. 2014 1319 47 65 10.1111/nyas.12469 24965257

244. Bunt S.K. Sinha P. Clements V.K. Leips J. Ostrand-Rosenberg S. Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression J. Immunol. 2006 176 284 290 10.4049/jimmunol.176.1.284 16365420

245. Shi H. Zhang J. Han X. Li H. Xie M. Sun Y. Liu W. Ba X. Zeng X. Recruited monocytic myeloid-derived suppressor cells promote the arrest of tumor cells in the premetastatic niche through an IL-1beta-mediated increase in E-selectin expression Int. J. Cancer 2017 140 1370 1383 10.1002/ijc.30538 27885671

246. Jiang H. Gebhardt C. Umansky L. Beckhove P. Schulze T.J. Utikal J. Umansky V. Elevated chronic inflammatory factors and myeloid-derived suppressor cells indicate poor prognosis in advanced melanoma patients Int. J. Cancer 2015 136 2352 2360 10.1002/ijc.29297 25353097

247. Sinha P. Clements V.K. Fulton A.M. Ostrand-Rosenberg S. Prostaglandin e2 promotes tumor progression by inducing myeloid-derived suppressor cells Cancer Res. 2007 67 4507 4513 10.1158/0008-5472.CAN-06-4174 17483367

248. Carmi Y. Dotan S. Rider P. Kaplanov I. White M.R. Baron R. Abutbul S. Huszar M. Dinarello C.A. Apte R.N. The role of IL-1beta in the early tumor cell-induced angiogenic response J. Immunol. 2013 190 3500 3509 10.4049/jimmunol.1202769 23475218

249. Vidal-Vanaclocha F. Fantuzzi G. Mendoza L. Fuentes A.M. Anasagasti M.J. Martin J. Carrascal T. Walsh P. Reznikov L.L. Kim S.H. IL-18 regulates IL-1beta-dependent hepatic melanoma metastasis via vascular cell adhesion molecule-1 Proc. Natl. Acad. Sci. USA 2000 97 734 739 10.1073/pnas.97.2.734 10639148 PMC15399

250. Chirivi R.G. Garofalo A. Padura I.M. Mantovani A. Giavazzi R. Interleukin 1 receptor antagonist inhibits the augmentation of metastasis induced by interleukin 1 or lipopolysaccharide in a human melanoma/nude mouse system Cancer Res. 1993 53 5051 5054 8267795

251. Erez N. Glanz S. Raz Y. Avivi C. Barshack I. Cancer associated fibroblasts express pro-inflammatory factors in human breast and ovarian tumors Biochem. Biophys. Res. Commun. 2013 437 397 402 10.1016/j.bbrc.2013.06.089 23831470

252. Cirri P. Chiarugi P. Cancer associated fibroblasts: The dark side of the coin Am. J. Cancer Res. 2011 1 482 497 21984967 PMC3186047

253. Kalluri R. Zeisberg E. Controlling angiogenesis in heart valves Nat. Med. 2006 12 1118 1119 10.1038/nm1006-1118 17024200

254. Santi A. Kugeratski F.G. Zanivan S. Cancer associated fibroblasts: The architects of stroma remodeling Proteomics 2018 18 e1700167 10.1002/pmic.201700167 29280568 PMC5900985

255. Aylon Y. Oren M. New plays in the p53 theater Curr. Opin. Genet. Dev. 2011 21 86 92 10.1016/j.gde.2010.10.002 21317061 PMC3059112

256. Schauer I.G. Zhang J. Xing Z. Guo X. Mercado-Uribe I. Sood A.K. Huang P. Liu J. Interleukin-1beta promotes ovarian tumorigenesis through a p53/NF-kappab-mediated inflammatory response in stromal fibroblasts Neoplasia 2013 15 409 420 10.1593/neo.121228 23555186 PMC3612913

257. Zhou P. Xiao N. Wang J. Wang Z. Zheng S. Shan S. Wang J. Du J. Wang J. Smc1a recruits tumor-associated-fibroblasts (TAFs) and promotes colorectal cancer metastasis Cancer Lett. 2017 385 39 45 10.1016/j.canlet.2016.10.041 27826041

258. De Marco P. Lappano R. De Francesco E.M. Cirillo F. Pupo M. Avino S. Vivacqua A. Abonante S. Picard D. Maggiolini M. Gper signalling in both cancer-associated fibroblasts and breast cancer cells mediates a feedforward IL1beta/IL1R1 response Sci. Rep. 2016 6 24354 10.1038/srep24354 27072893 PMC4829876

259. Liotta L.A. Kohn E.C. The microenvironment of the tumour-host interface Nature 2001 411 375 379 10.1038/35077241 11357145

260. Voronov E. Shouval D.S. Krelin Y. Cagnano E. Benharroch D. Iwakura Y. Dinarello C.A. Apte R.N. IL-1 is required for tumor invasiveness and angiogenesis Proc. Natl. Acad. Sci. USA 2003 100 2645 2650 10.1073/pnas.0437939100 12598651 PMC151394

261. Saijo Y. Tanaka M. Miki M. Usui K. Suzuki T. Maemondo M. Hong X. Tazawa R. Kikuchi T. Matsushima K. Proinflammatory cytokine IL-1 beta promotes tumor growth of lewis lung carcinoma by induction of angiogenic factors: In vivo analysis of tumor-stromal interaction J. Immunol. 2002 169 469 475 10.4049/jimmunol.169.1.469 12077278

262. Nakao S. Kuwano T. Tsutsumi-Miyahara C. Ueda S. Kimura Y.N. Hamano S. Sonoda K.H. Saijo Y. Nukiwa T. Strieter R.M. Infiltration of COX-2-expressing macrophages is a prerequisite for IL-1 beta-induced neovascularization and tumor growth J. Clin. Investig. 2005 115 2979 2991 10.1172/JCI23298 16239969 PMC1257532

263. Woodhouse E.C. Chuaqui R.F. Liotta L.A. General mechanisms of metastasis Cancer 1997 80 1529 1537 10.1002/(SICI)1097-0142(19971015)80:8+<1529::AID-CNCR2>3.0.CO;2-F 9362419

264. Psaila B. Lyden D. The metastatic niche: Adapting the foreign soil Nat. Rev. Cancer 2009 9 285 293 10.1038/nrc2621 19308068 PMC3682494

265. Sceneay J. Smyth M.J. Moller A. The pre-metastatic niche: Finding common ground Cancer Metastasis Rev. 2013 32 449 464 10.1007/s10555-013-9420-1 23636348

266. Giavazzi R. Garofalo A. Bani M.R. Abbate M. Ghezzi P. Boraschi D. Mantovani A. Dejana E. Interleukin 1-induced augmentation of experimental metastases from a human melanoma in nude mice Cancer Res. 1990 50 4771 4775 2196116

267. Kaplan R.N. Riba R.D. Zacharoulis S. Bramley A.H. Vincent L. Costa C. MacDonald D.D. Jin D.K. Shido K. Kerns S.A. Vegfr1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche Nature 2005 438 820 827 10.1038/nature04186 16341007 PMC2945882

268. Wang H. Luo Q. Feng X. Zhang R. Li J. Chen F. NLRP3 promotes tumor growth and metastasis in human oral squamous cell carcinoma BMC Cancer 2018 18 500 10.1186/s12885-018-4403-9 29716544 PMC5930757

269. Vidal-Vanaclocha F. Amezaga C. Asumendi A. Kaplanski G. Dinarello C.A. Interleukin-1 receptor blockade reduces the number and size of murine B16 melanoma hepatic metastases Cancer Res. 1994 54 2667 2672 8168095

270. Vidal-Vanaclocha F. Alvarez A. Asumendi A. Urcelay B. Tonino P. Dinarello C.A. Interleukin 1 (IL-1)-dependent melanoma hepatic metastasis in vivo; increased endothelial adherence by IL-1-induced mannose receptors and growth factor production in vitro J. Natl. Cancer Inst. 1996 88 198 205 10.1093/jnci/88.3-4.198 8632494

271. Carrascal M.T. Mendoza L. Valcarcel M. Salado C. Egilegor E. Telleria N. Vidal-Vanaclocha F. Dinarello C.A. Interleukin-18 binding protein reduces B16 melanoma hepatic metastasis by neutralizing adhesiveness and growth factors of sinusoidal endothelium Cancer Res. 2003 63 491 497 12543807

272. Smith L.B. Leo M.C. Anderson C. Wright T.J. Weymann K.B. Wood L.J. The role of IL-1beta and TNF-alpha signaling in the genesis of cancer treatment related symptoms (CTRS): A study using cytokine receptor-deficient mice Brain Behav. Immun. 2014 38 66 76 10.1016/j.bbi.2013.12.022 24412646 PMC3989411

273. Wong J. Tran L.T. Magun E.A. Magun B.E. Wood L.J. Production of IL-1beta by bone marrow-derived macrophages in response to chemotherapeutic drugs: Synergistic effects of doxorubicin and vincristine Cancer Biol. Ther. 2014 15 1395 1403 10.4161/cbt.29922 25046000 PMC4130732

274. Dummer R. Ascierto P.A. Gogas H.J. Arance A. Mandala M. Liszkay G. Garbe C. Schadendorf D. Krajsova I. Gutzmer R. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with braf-mutant melanoma (columbus): A multicentre, open-label, randomised phase 3 trial Lancet Oncol. 2018 19 603 615 10.1016/S1470-2045(18)30142-6 29573941

275. Kulkarni D. Song K. Briley L. King K. Dabrowski C. Mookerjee B. Legos J. Spraggs C. Pyrexia in dabrafenib-treated melanoma patients is not associated with common genetic variation or HLA polymorphisms Pharmacogenomics 2016 17 459 462 10.2217/pgs.16.4 27023328

276. Westbom C. Thompson J.K. Leggett A. MacPherson M. Beuschel S. Pass H. Vacek P. Shukla A. Inflammasome modulation by chemotherapeutics in malignant mesothelioma PLoS ONE 2015 10 e0145404 10.1371/journal.pone.0145404 26689911 PMC4687055

277. Young H.L. Rowling E.J. Bugatti M. Giurisato E. Luheshi N. Arozarena I. Acosta J.C. Kamarashev J. Frederick D.T. Cooper Z.A. An adaptive signaling network in melanoma inflammatory niches confers tolerance to mapk signaling inhibition J. Exp. Med. 2017 214 1691 1710 10.1084/jem.20160855 28450382 PMC5460994

278. Voloshin T. Alishekevitz D. Kaneti L. Miller V. Isakov E. Kaplanov I. Voronov E. Fremder E. Benhar M. Machluf M. Blocking il1beta pathway following paclitaxel chemotherapy slightly inhibits primary tumor growth but promotes spontaneous metastasis Mol. Cancer Ther. 2015 14 1385 1394 10.1158/1535-7163.MCT-14-0969 25887886

279. Ren H.Y. Liu F. Huang G.L. Liu Y. Shen J.X. Zhou P. Liu W.M. Shen D.Y. Positive feedback loop of IL-1beta/Akt/RARalpha/Akt signaling mediates oncogenic property of raralpha in gastric carcinoma Oncotarget 2017 8 6718 6729 28035062 10.18632/oncotarget.14267 PMC5351665

280. Huang F.Y. Chan A.O. Lo R.C. Rashid A. Wong D.K. Cho C.H. Lai C.L. Yuen M.F. Characterization of interleukin-1beta in helicobacter pylori-induced gastric inflammation and DNA methylation in interleukin-1 receptor type 1 knockout (IL-1R1 -/- ) mice Eur. J. Cancer 2013 49 2760 2770 10.1016/j.ejca.2013.03.031 23664095

281. Sauter K.A. Wood L.J. Wong J. Iordanov M. Magun B.E. Doxorubicin and daunorubicin induce processing and release of interleukin-1beta through activation of the nlrp3 inflammasome Cancer Biol. Ther. 2011 11 1008 1016 10.4161/cbt.11.12.15540 21464611 PMC3142364

282. Wong J. Smith L.B. Magun E.A. Engstrom T. Kelley-Howard K. Jandhyala D.M. Thorpe C.M. Magun B.E. Wood L.J. Small molecule kinase inhibitors block the ZAK-dependent inflammatory effects of doxorubicin Cancer Biol. Ther. 2013 14 56 63 10.4161/cbt.22628 23114643 PMC3566053

283. Antonopoulos C. El Sanadi C. Kaiser W.J. Mocarski E.S. Dubyak G.R. Proapoptotic chemotherapeutic drugs induce noncanonical processing and release of IL-1beta via caspase-8 in dendritic cells J. Immunol. 2013 191 4789 4803 10.4049/jimmunol.1300645 24078693 PMC3870469

284. Lee D.W. Faubel S. Edelstein C.L. A pan caspase inhibitor decreases caspase-1, IL-1alpha and IL-1beta, and protects against necrosis of cisplatin-treated freshly isolated proximal tubules Ren. Fail. 2015 37 144 150 10.3109/0886022X.2014.970194 25310769

285. Zhang Y. Yuan F. Cao X. Zhai Z. GangHuang Du X. Wang Y. Zhang J. Huang Y. Zhao J. P2X7 receptor blockade protects against cisplatin-induced nephrotoxicity in mice by decreasing the activities of inflammasome components, oxidative stress and caspase-3 Toxicol. Appl. Pharmacol. 2014 281 1 10 10.1016/j.taap.2014.09.016 25308879

286. Jia M. Wu C. Gao F. Xiang H. Sun N. Peng P. Li J. Yuan X. Li H. Meng X. Activation of NLRP3 inflammasome in peripheral nerve contributes to paclitaxel-induced neuropathic pain Mol. Pain 2017 13 10.1177/1744806917719804 28714351 PMC5562344

287. Ledeboer A. Jekich B.M. Sloane E.M. Mahoney J.H. Langer S.J. Milligan E.D. Martin D. Maier S.F. Johnson K.W. Leinwand L.A. Intrathecal interleukin-10 gene therapy attenuates paclitaxel-induced mechanical allodynia and proinflammatory cytokine expression in dorsal root ganglia in rats Brain Behav. Immun. 2007 21 686 698 10.1016/j.bbi.2006.10.012 17174526 PMC2063454

288. Bruchard M. Mignot G. Derangere V. Chalmin F. Chevriaux A. Vegran F. Boireau W. Simon B. Ryffel B. Connat J.L. Chemotherapy-triggered cathepsin b release in myeloid-derived suppressor cells activates the nlrp3 inflammasome and promotes tumor growth Nat. Med. 2013 19 57 64 10.1038/nm.2999 23202296

289. Zitvogel L. Kepp O. Galluzzi L. Kroemer G. Inflammasomes in carcinogenesis and anticancer immune responses Nat. Immunol. 2012 13 343 351 10.1038/ni.2224 22430787

290. Sota J. Vitale A. Insalaco A. Sfriso P. Lopalco G. Emmi G. Cattalini M. Manna R. Cimaz R. Priori R. Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: A nationwide multicenter retrospective observational study Clin. Rheumatol. 2018 10.1007/s10067-018-4119-x 29770930

291. Anasagasti M.J. Olaso E. Calvo F. Mendoza L. Martin J.J. Bidaurrazaga J. Vidal-Vanaclocha F. Interleukin 1-dependent and -independent mouse melanoma metastases J. Natl. Cancer Inst. 1997 89 645 651 10.1093/jnci/89.9.645 9150189

292. Yu G.T. Bu L.L. Zhao Y.Y. Mao L. Deng W.W. Wu T.F. Zhang W.F. Sun Z.J. CTLA4 blockade reduces immature myeloid cells in head and neck squamous cell carcinoma Oncoimmunology 2016 5 e1151594 10.1080/2162402X.2016.1151594 27471622 PMC4938362

293. Deng W.W. Mao L. Yu G.T. Bu L.L. Ma S.R. Liu B. Gutkind J.S. Kulkarni A.B. Zhang W.F. Sun Z.J. LAG-3 confers poor prognosis and its blockade reshapes antitumor response in head and neck squamous cell carcinoma Oncoimmunology 2016 5 e1239005 10.1080/2162402X.2016.1239005 27999760 PMC5139652

294. Reed J.R. Leon R.P. Hall M.K. Schwertfeger K.L. Interleukin-1beta and fibroblast growth factor receptor 1 cooperate to induce cyclooxygenase-2 during early mammary tumourigenesis Breast Cancer Res. 2009 11 R21 10.1186/bcr2246 19393083 PMC2688950

295. Zhou W. Guo S. Gonzalez-Perez R.R. Leptin pro-angiogenic signature in breast cancer is linked to IL-1 signalling Br. J. Cancer 2011 104 128 137 10.1038/sj.bjc.6606013 21139583 PMC3039812

296. Lipsey C.C. Harbuzariu A. Daley-Brown D. Gonzalez-Perez R.R. Oncogenic role of leptin and notch interleukin-1 leptin crosstalk outcome in cancer World J. Methodol. 2016 6 43 55 10.5662/wjm.v6.i1.43 27019796 PMC4804251

297. Weichand B. Popp R. Dziumbla S. Mora J. Strack E. Elwakeel E. Frank A.C. Scholich K. Pierre S. Syed S.N. S1PR1 on tumor-associated macrophages promotes lymphangiogenesis and metastasis via nlrp3/IL-1beta J. Exp. Med. 2017 214 2695 2713 10.1084/jem.20160392 28739604 PMC5584110